
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)13665-1
10.1016/j.heliyon.2024.e37634
e37634
Review Article
Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems
Bharathi Jothi Kanmani a
Suresh Preethika bc
Prakash Muthu Arjuna Samy geeth_prakash@yahoo.co.in
a⁎⁎
Muneer Sowbiya sowbiya.muneer@vit.ac.in
c⁎
a Department of Genetics and Plant Breeding, Faculty of Agriculture, Annamalai University, Annamalai Nagar, 608002, Tamil Nadu, India
b School of Bioscience and Biotechnology, Vellore Institute of Technology, Vellore, Tamil-Nadu, India
c Department of Horticulture and Food Science, School of Agricultural Innovations and Advanced Learning, Vellore Institute of Technology, Vellore, Tamil-Nadu, India
⁎ Corresponding author. sowbiya.muneer@vit.ac.in
⁎⁎ Corresponding author. geeth_prakash@yahoo.co.in
07 9 2024
30 9 2024
07 9 2024
10 18 e3763416 4 2024
10 8 2024
6 9 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
An excellent technique for producing pharmaceuticals called "molecular farming" enables the industrial mass production of useful recombinant proteins in genetically modified organisms. Protein-based pharmaceuticals are rising in significance because of a variety of factors, including their bioreactivity, precision, safety, and efficacy rate. Heterologous expression methods for the manufacturing of pharmaceutical products have been previously employed using yeast, bacteria, and animal cells. However, the high cost of mammalian cell system, and production, the chance for product complexity, and contamination, and the hurdles of scaling up to commercial production are the limitations of these traditional expression methods. Plants have been raised as a hopeful replacement system for the expression of biopharmaceutical products due to their potential benefits, which include low production costs, simplicity in scaling up to commercial manufacturing levels, and a lower threat of mammalian toxin contaminations and virus infections. Since plants are widely utilized as a source of therapeutic chemicals, molecular farming offers a unique way to produce molecular medicines such as recombinant antibodies, enzymes, growth factors, plasma proteins, and vaccines whose molecular basis for use in therapy is well established. Biopharming provides more economical and extensive pharmaceutical drug supplies, including vaccines for contagious diseases and pharmaceutical proteins for the treatment of conditions like heart disease and cancer. To assess its technical viability and the efficacy resulting from the adoption of molecular farming products, the following review explores the various methods and methodologies that are currently employed to create commercially valuable molecules in plant systems.

Graphical abstract

Image 1

Highlights

• Plant molecular farming offers economic advantages for producing a variety of products, including pharmaceuticals and industrial proteins, with fewer restrictions.

• Plants can be engineered to produce antibodies for targeted treatment, showing promise in fighting infections.

• Regulatory complexities pose a barrier to broad adoption of plant systems for therapeutic protein production, while non-pharmaceutical proteins benefit from easier commercialization.

• Research is needed to identify mid-to-high-value by-products from biomass leftover in the manufacturing process, enhancing process income and sustainability.

Keywords

Plant molecular farming
Biopharming
Plantibody
Plant-based vaccines
recombinant proteins
==== Body
pmc Abbreviations

BTV	Bluetongue virus	
BVDV	Bovine viral diarrhea virus	
CCHFV	Crimean-Congo haemorrhagic fever virus	
CHIKV	chikungunya virus	
CoOMT	Columbamine O-methyltransferase	
CP	Capsid protein	
CPMV-HT	Cowpea mosaic virus based HyperTrans	
CTB	Cholera toxin	
CTB-GFP	Cholera toxin B-subunit and green fluorescent protein	
EIC	Ebola immune complex	
EIII	E glycoprotein domain III	
ETEC	Enterotoxigenic E. coli	
EHEC	Enterohemorrhagic E. coli	
FaeG	F4 fimbrial adhesin	
Fc	Fragment crystallizable	
FhCMB	Fraunhofer USA Center for Molecular Biotechnology	
FimA	Fimbrial protein fimbrillin	
Flu	Influenza	
FMDV	Foot and mouth disease virus	
GCase	Glucocerebrosidase	
GD	Gaucher disease	
GP	Glycoprotein	
GTFs	Glycosyltransferases	
H1N1	Human influenza strains	
H2GP1	Heavy chain-GP1 fusion protein	
H5N1	Avian influenza virus	
HAs	Haemagglutinin	
HBsAg	Hepatitis B surface antigen	
HBV	Hepatitis B virus	
H-chain	Heavy chain	
hGH	Human growth hormone	
HIV	Human immunodeficiency virus	
HPV	Human papillomavirus	
HR	Hairy roots	
hSA	Human serum albumin	
IBDV	Infectious bursal disease virus	
IBV	Infectious bronchitis virus	
LFM	Leaf fresh mass	
LT-B	Heat-labile enterotoxin B subunit	
mAb	Monoclonal antibody	
MF	Molecular farming	
MOMP	Major outer membrane protein	
NaV	Narita 104 virus	
NDV	Newcastle disease virus	
NV	Norwalk virus	
PA	Protective antigen	
PMF	Plant molecular farming	
PMPs	Plant-made pharmaceuticals	
PRRSV	Porcine reproductive and respiratory syndrome virus	
PzE	Plant-produced zE	
QVLP	Quadrivalent virus-like particle	
r-antibody	Recombinant antibody	
r-antigen	Recombinant antigen	
RBD	Receptor binding domain	
RGP-RTB	Rabies Glycoprotein, Ricin Toxin B Chain	
RHDV	Rabbit hemorrhagic disease virus	
rNV	Recombinant Norwalk virus	
r-protein	Recombinant protein	
RV	Rotaviruses	
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	
sIgA	Secretory immunoglobulins A	
sIgM	Secretory immunoglobulins M	
TGEV	Transmissible gastroenteritis virus	
VLP	Virus-like particles	
WNV	West Nile virus	
WT	Wild type	
zE	ZIKV envelope E	
ZIKV	Zika virus	

1 Introduction

Molecular farming (MF) uses plants as factories to produce valuable proteins like pharmaceuticals through genetic modification [1]. The first recombinant human proteins, growth hormone, and insulin were created in the 1980s by the bacteria Escherichia coli, which marked the beginning of molecular farming. The first industrial MF process was introduced in 1996 and featured the synthesis of protein-based technological chemicals in maize seeds [2]. Plants have always given humans useful products, but over the past 30 years, they have also been used to create small molecules and recombinant proteins (r-proteins). Due to the expansion of the global bioeconomy, this once-niche field has developed and is now the residence of renewable energy sources, chemical building blocks, and polymers. All these uses fall under the category of "plant molecular farming" (PMF). The market for PMF products was estimated to be worth $116.1 million in 2021 and is predicted to grow to $182.9 million by 2031 [3]. The use of pharmacologically active proteins in a range of clinical therapies has undergone a revolution because of research in recent years. It is crucial to choose which system gives the greatest benefits for the synthesis of the r-protein because the majority of genes may be expressed in a variety of systems [4]. PMF hasn't been widely adopted by industry despite its promise to improve the viability of biologics manufacturing [5]. Human biopharmaceuticals, dietary supplements, recombinant antibodies, biodegradable polymers, recombinant vaccine subunits, and several other nonpharmaceuticals have all been successfully fabricated in plants in recent decades. Several therapeutic products, such as diagnostic proteins (enzymes and antibodies), protein replacements (insulin for diabetics, factor VIII for hemophiliacs), immune system stimulators/suppressants (colony-stimulating factors, interferons, and interleukins), adhere proteins and biopolymers for surgical uses, and growth factors (GF) can all be produced in plants [6]. Over a hundred distinct heterologous proteins, including hormones, antigens, enzymes, anticoagulant peptides, antibodies, and molecular transporters been produced in various plant systems since 1986, whereas human growth hormone (hGH), the first significant recombinant pharmaceutics, was initially developed in transgenic tobacco and sunflower cells [7]. However, the earliest commercially useful recombinant egg protein avidin was not produced in transgenic maize until 1997 [8]. Whereas entire crops like cereals and tobacco are frequently used in MF, additional plant-based systems are also included in this technique such as algae, moss, aquatic plants, and even in vitro gene expression networks made from plant cells [1]. It has been largely facilitated by their ability to make post-translational changes that ensure proper folding and keeping of structural and functional integrity of these r-proteins [9]. PMF technologies are getting attention from researchers throughout the world because of the continuous rise in the urges for r-proteins in terms of quantity, quality, and variety [10,10]. Human serum albumin (hSA), insulin, and HIV-neutralizing antibodies are instances of plant-made pharmaceuticals (PMPs) with international markets. Because of the widespread prevalence of diabetes, including a major undersupplied market in Asia, human insulin is in great demand. This insulin shortage might be filled by plant production at a cost that diabetics in this area could afford [11]. A rice-derived hSA called Optibumin was produced by InVitria, a branch of Ventria Bioscience, and it has already achieved mainstream success [12]. In 2012, the market saw the release of the first plant-based recombinant medication licensed for use by people [2]. Plants are now a desirable production platform that can even attain economically pertinent production in a relatively short time because of improvements in PMF techniques over the last decades [10]. This review on MF in plant systems stands out for its focus on recent advancements, comprehensive coverage of plant-based vaccine and therapeutic protein production, emphasis on safety and regulatory aspects, discussion of economic viability, sustainability, and future perspectives.

2 Tools and approaches of MF

2.1 Expression strategies for MF

Chromosomal incorporation of a heterologous gene is necessary for plant transformation, and it is getting easier. Technical and practical challenges must be resolved, such as creating potential transformation methods for all important crop species [13]. Recently, there are three methods for creating PMF products (Fig. 1).Fig. 1 Schematic delineation of plant molecular farming. A. Selection of candidate gene and expression vector design. B. Available plant-based production systems: a. Stable expression system produced by either nuclear transformation using agrobacterium, or chloroplast transformation using gene gun. b. Cell suspension of transgenic callus was cultured in a bioreactor. c. Transient/Temporary expression system produced by plant viral injection and agrobacterium infiltration. C. Popular recombinant products produced in the PMF system. D. Form of MF products utilized for commercialization.

Fig. 1

2.1.1 Stable/permanent expression

This approach needs a technique for introducing the foreign genes into the plant cells that will allow them to be taken up and steadily integrated into the host nuclear genome, by utilizing Agrobacterium tumefaciens (for dicots) or particle bombardment (for monocots) [13]. Long-term recombinant product synthesis is possible because these transformations produce stable recombinant products that can be passed down from generation to generation [14]. Other classifications of stable/permanent expression systems include the following.a. Nuclear transformation: All the items that are now on the market were developed mostly by using the nuclear transformation of plant species. This approach has several benefits. The protein product often accumulates inside the seeds when applied to a crop species like grains. They are then collected in dry condition and kept in storage until processing is finished. Also, this method may be used for huge areas at the least expensive. Even so, developing a permanent transgenic plant might take months or even years based on the plant type employed for r-protein production. The ability of some crops, like maize, which hybridize with local species or food crops is another drawback of this approach [14].

b. Plastid transformation: This process relies on the homologous recombination of target genes into chloroplast genome sequences. The nuclear transformation has many drawbacks, including the potential for transgene escape by amphimixis. Plastid transformation extends multiple benefits over nuclear transformation. Several species pass their plastids through their maternal tissue, therefore the absence of chloroplasts in most pollen species minimizes environmental issues. The drawback of this approach is that product stability would deteriorate with time in any fresh tissue MF system [15].

2.1.2 Transient expression

Transgenic plants are usually utilized to produce recombinant products. However, it requires a huge time to develop transgenics, and protein expression is relatively less instead, r-proteins can be expressed quickly at elevated levels using transient expression methods. This is because agroinfiltration employing biolistics, viral vectors, or agrobacteria can be done. Agroinfiltration makes use of vacuum infiltration to introduce Agrobacteria into healthy leaf tissue. Incorporating required genes into the host cells simplifies protein production in leaf tissues. The target gene is usually regulated by a strong sub-genomic promoter and cloned into the genome of a plant pathogenic virus. The r-protein is then produced by plants that have been infected with pathogenic recombinant viral transcripts. The foreign genetic material does not incorporate into the plant's genome during temporary expression. Transient expression can be performed in experimental trials prior to the prolonged and expensive stable transformation [16].

2.1.3 Cell suspension culture

Transgenic calluses were suspended with liquid growth media in bioreactors. This method enables the large-scale production of MF products [17]. Each strategy offers unique benefits and limitations in terms of protein expression, scalability, production efficiency, and regulatory considerations. Table 1 highlights the advantages, drawbacks, and strategies for overcoming challenges associated with nuclear transformation, plastid transformation, transient expression, and cell suspension systems.Table 1 Comparison of advantages and limitations of expression strategies in plant systems.

Table 1Expression strategies	Advantages	Drawbacks	Strategies for overcome the problems	
Nuclear transformation	• Heritable expression of recombinant proteins.

• Ability to produce proteins in seeds for easy storage and processing.

• Cost-effective production on a large scale.

• Potential for proximity to target markets due to widespread cultivation of crop species like rice and corn.

• Established method for producing all products available in the market.

• Suitable for long-term recombinant protein production [14].

	• Time-consuming development of stably transformed plants.

• Potential for crossbreeding with native species or food crops.

• Higher manual labour requirements and lower yields in some cases.

• Concerns about transgene escape and outcrossing.

• Limited scalability for producing large quantities of products.

• Challenges in regulating protein stability over time and post-harvest processing [14].

	• Enhance Transformation Efficiency: Improving the efficiency of gene transfer methods is crucial. This can be achieved by optimizing transformation protocols, selecting appropriate vectors, and enhancing the integration of foreign genes into the plant genome. Increasing the success rate of stable transformation will lead to higher yields of recombinant proteins.

• Choose Host Plants Wisely: Selecting plant species that are well-suited for stable transformation and have high protein expression capabilities is essential. Opting for crop species with established transformation protocols and favourable characteristics for protein production can streamline the process and improve overall efficiency.

• Design High-Expression Constructs: Developing expression constructs that promote high levels of protein expression and stability in plant cells is key. Utilizing strong promoters, suitable signal peptides, and codon optimization can enhance protein production efficiency and ensure robust expression of the desired recombinant proteins.

• Streamline Downstream Processing: Optimizing downstream processing steps, such as protein extraction, purification, and formulation, is critical. Implementing efficient purification techniques tailored to plant-derived proteins can improve product quality, increase yield, and reduce production costs.

• Control Transgene Expression: Implementing strategies to regulate transgene expression levels can prevent unintended effects on plant physiology. Using inducible promoters or tissue-specific expression systems can help control protein production, minimize potential negative impacts on plant growth, and ensure proper protein expression.

• Manage Environmental Concerns: Addressing environmental concerns related to transgenic plants is essential. Implementing containment measures, such as mechanical detasseling or genetic male sterility, can prevent gene flow and mitigate the risk of transgene escape, ensuring environmental safety and regulatory compliance [56].

	
Plastid transformation	• Prevention of transgene escape through amphimixis.

• Inheritance through maternal tissue in most species.

• Reduced environmental concerns due to the absence of chloroplasts in most pollen.

• Potential for high levels of protein expression, with reports of up to 70 % of total soluble proteins.

• Ability to produce pharmaceutical proteins in high concentrations.

• Superior solution compared to nuclear transformation in certain aspects [196].

	• Changes in protein stability over time in fresh tissue systems, requiring precise timing for extraction and purification.

• Limited scalability for producing large quantities of products.

• Challenges in post-harvest processing due to the need for extraction and purification at specific times.

• Restrictions on the use of certain crops like tobacco, which is a highly regulated crop and not edible.

• Concerns about the system's capability to produce edible vaccines or large quantities of products.

• Potential limitations in terms of yield and effectiveness compared to other transformation methods [196].

	• Implement strict timing protocols for extraction and purification to maintain protein stability over time.

• Explore alternative crops or species that are more suitable for plastid transformation and have higher scalability for production.

• Develop methods to enhance protein yield and effectiveness within the plastid transformation system.

• Investigate ways to improve post-harvest processing techniques to optimize protein extraction and purification.

• Conduct research on enhancing the capabilities of plastid transformation for producing edible vaccines and large quantities of products.

• Collaborate with regulatory bodies to address concerns about using regulated crops like tobacco and explore options for utilizing other edible plant species for plastid transformation [61].

	
Transient expression	• Rapid production of recombinant proteins in a matter of days, allowing for quick response to emergencies.

• Ability to close production gaps quickly in response to new antigen sequences.

• Flexibility to produce various types of proteins, such as subunit vaccines, in raw or partially processed fruits and vegetables.

• Suitable for developing emergency vaccines and diagnostics, such as those for novel influenza virus strains and SARS-CoV-2.

• Speedy production capacities that are crucial during emergency scenarios when other drug production cannot be delayed.

• Effective strategy for producing diagnostics and therapeutics against emerging diseases like SARS-CoV-2 [14].

	• Limited scalability for large-scale production compared to stable transformation methods.

• Challenges in producing proteins that need to be consumed in large quantities.

• Requirement for immediate processing of the product as storage can lead to plant tissue degradation.

• Potential issues with protein stability and expression levels compared to stable transformation methods.

• Not suitable for long-term production of certain proteins that require sustained expression.

	• Optimization of Expression Conditions: Fine-tuning the parameters of transient expression, such as the choice of promoter, vector design, infiltration method, and post-translational modification signals, can help improve protein yield, stability, and consistency.

• Enhancing Protein Stability: Incorporating protein stabilization motifs or chaperones in the expression construct can improve the stability and correct folding of transiently produced proteins, reducing the risk of degradation or misfolding.

• Batch-to-Batch Consistency: Implementing quality control measures and standardized protocols for transient expression can help ensure consistency in protein expression levels and quality across different plant batches or experiments.

• Scale-Up Strategies: Developing efficient scale-up strategies for transient expression, such as optimizing production facilities, automation of processes, and implementing robust purification methods, can facilitate large-scale manufacturing while maintaining protein quality and yield.

• Regulatory Compliance: Engaging with regulatory authorities early in the development process, conducting thorough risk assessments, and ensuring compliance with relevant regulations can help address regulatory concerns associated with products derived from transient expression systems.

• Cost-Effectiveness: Conducting cost-benefit analyses, optimizing production processes for efficiency, and exploring novel technologies or platforms that enhance the cost-effectiveness of transient expression can help mitigate the economic challenges associated with this expression system.

• Hybrid Approaches: Combining transient expression with stable transformation methods, such as using transient systems for rapid protein screening and optimization before transitioning to stable transgenic production for large-scale manufacturing, can leverage the strengths of both systems [43].

	
Cell suspension	• Ability to produce high-value bioactive compounds in some plant species.

• Ease of scale-up for manufacturing purposes.

• Aseptic conditions can be maintained during growth using traditional fermentation technology.

• Simplified purification process due to no tissue disruption requirement and low contaminating proteins.

• Regulatory requirements similar to well-characterized production systems based on microbial and mammalian cells.

• Reduction in heterogeneity of proteins and sugar in terms of cell type and size uniformity.

• Faster system compared to transgenic plant production, with cell lines being produced in a few months.

• Potential to become the preferred choice among plant-based systems for producing high-value recombinant proteins due to combining benefits of other systems [17].

	• Proteins produced in cell suspension cultures may not always fold correctly or undergo proper post-translational modifications, leading to reduced functionality or efficacy of the recombinant proteins.

• Obtaining regulatory approval for products derived from cell suspension cultures may be more complex due to concerns about cell culture contaminants, potential adventitious agent presence, and the use of bioreactors in production, necessitating thorough compliance with regulatory requirements.

• Prolonged culture periods in cell suspension cultures may lead to genetic changes or drift in cell lines, which can impact protein expression levels, stability, or other characteristics. Regular monitoring and maintenance of cell lines are essential to mitigate this risk.

• caling up cell suspension cultures from small laboratory volumes to industrial-scale bioreactors can be challenging, requiring careful optimization of culture conditions, nutrient supply, and oxygenation to maintain optimal growth and protein production.

• he initial investment and operational expenses associated with setting up and maintaining cell suspension cultures in bioreactors can be significant, potentially making this production system more costly compared to other expression platforms.

• Recombinant proteins expressed in plant cell suspension cultures may not always be efficiently secreted into the supernatant, leading to variability in the amount of protein recovered. Some of the protein may be retained within the cells, affecting overall productivity and product quality [17].

	• Optimization of Culture Conditions: Fine-tuning the culture conditions, including nutrient composition, pH levels, temperature, and aeration, can help improve cell growth and protein production in suspension cultures. Optimization of these parameters can enhance productivity and protein yields.

• Selection of High-Producing Cell Lines: Identifying and selecting cell lines with high protein production capabilities can significantly improve the efficiency of molecular farming using suspension cultures. Screening and optimizing cell lines for specific proteins of interest can enhance production levels 5.

• Genetic Engineering: Implementing genetic engineering techniques to enhance protein expression in cell suspension cultures can be beneficial. Strategies such as gene stacking, promoter optimization, and gene editing can boost protein yields and improve the efficiency of molecular farming 5.

• Bioreactor Design and Scale-Up: Utilizing advanced bioreactor systems and scaling up suspension culture production processes can help overcome limitations in scalability and production volume. Designing bioreactors for optimal cell growth and protein expression can increase overall productivity 5.

• Purification and Downstream Processing: Developing efficient purification and downstream processing methods for extracting and purifying recombinant proteins from cell suspension cultures is essential. Streamlining these processes can improve protein quality, yield, and overall production efficiency 5.

• Risk Mitigation Strategies: Implementing biocontainment measures and risk mitigation strategies to prevent contamination and maintain the integrity of cell suspension cultures is important. Proper containment protocols and sterile techniques can help minimize the risk of cross-contamination and ensure product quality 5.

• Regulatory Compliance: Ensuring compliance with regulatory guidelines and quality standards for products derived from cell suspension cultures is crucial. Adhering to regulatory requirements and conducting thorough quality control assessments can facilitate the approval and commercialization of molecular farming products [43].

	

2.2 Improving PMF product quality and yield

The large-scale cultivation of some species was previously unsuitable or not suggested for traditional agriculture which raises several practical concerns. In the case of platforms based on plant-derived products, expression persistence, and product biochemical activity are crucial. It can be challenging to assess how well an expression construct performs across species since the inherent level of activity and specificity of a promoter might vary depending on the genetic background [18].

2.2.1 Targeted gene insertion

Particle bombardment or Agrobacterium tumefaciens, the conventional approach of gene transformation, produces random transgene integration. Variable expression levels result from position effects and varying transgene copy numbers caused by the inability to regulate the insertion event. Position effects comprise transgenic insertion near native regulatory elements and in genomic sites with distinct chromatin construction. Moreover, long-term transgene expression stability can be lowered by epigenetic alterations like methylation at the insertion site, which eventually results in a decline in productivity [19]. Site-specific nucleases (SSNs) provide a solution to the problems associated with random transgene incorporation. SSNs allow for the regulated integration of transgenes by creating a double-strand break (DSB) at a desired region. Because site-specific DNA insertion is not the desired result of DSB repairs in plants, it is still more difficult than SSN-induced indel creation. Although SSN-approach has not yet been employed especially for PMF programs, it has been documented in a few research involving a variety of species, such as arabidopsis, maize, barley, potato, rice, soybean, and tobacco [[20], [21], [22], [23], [24], [25]]. Additionally, Numerous benefits are provided by chloroplast genetic engineering (CGE) for large-scale production. Initially, it permits r-proteins to be expressed at a high level in plant chloroplasts, leading to higher yields of the target product. Furthermore, transgene confinement through maternal inheritance is made possible by CGE, which maintains genetic stability and stops transgene flow to wild populations. Because chloroplasts have several copies of the transgene and provide higher protein yields per plant cell, they are also a cost-effective option for protein expression. Additionally, this method is especially beneficial for leaf-based expression, offering a productive platform for r-protein production in plant leaves. Finally, the scalable nature of CGE makes it easier to produce huge amounts of r-proteins to satisfy market demands [26]. For example.

2.2.2 Expression vector constructs

The production of r-protein with a substantial expression yield is one of the goals of MF. r-protein expression constructs need to be adjusted at every step, from transcript stability to protein stability, to produce significant expression yields. It has been proposed recently that r-protein accumulation is not solely influenced by the guanine-cytosine composition of the target gene. Codon–anticodon dynamics is another significant factor that could have a significant impact on translation efficacy [27]. Most plant expression vectors are chimeric structures made from repurposed plant viruses, including potato virus X (PVX), cowpea mosaic virus (CPMV), alfalfa mosaic virus, and tobacco mosaic virus (TMV). The newest virus-based vectors are disassembled vectors in which the virus's non-essential genes have been substituted with the coding sequences of target genes or genes that promote high translation. The MagnICON system, the most renowned transient expression system, depends on constructs containing a PVX and a TMV backbone. A well-liked substitute is the pEAQ-HT expression system, which is derived from the CPMV and a variation that enhanced plant transient expression by logically creating synthetic 5′ and 3′ untranslated sections, ultimately leading to the creation of the pHREAC expression system [28]. Dicotyledonous plants have a strong constitutive promoter of the generated RNA transcripts, and the most often used promoter for these plants is CaMV 35S. The machinery of the cell will cap the emerging RNA transcripts at the 5′ end, which is necessary for translation in concert with the poly (A) tail. Duplicating the enhancer region can increase the CaMV 35S promoter's activity. But in monocotyledonous plants, this promoter exhibits reduced activity; hence, the maize ubiquitin-1 promoter is a better substitute [29].

2.2.3 Codon optimization

A recent study found that in tobacco BY-2 cells, codon optimization increased the output of a recombinant stem cell factor protein by 25 to 30-fold [30]. However, reports about the outcomes of codon optimization are similarly inconsistent. For instance, there was a minimal increase in protein yield when the interferon-γ or human erythropoietin genes were optimized for plant expression [31]. Similar findings were made when optimizing codon usage for the development of the HPV-16 L1 capsid protein in N. benthamiana. It was discovered that native genes with human codon usage performed better than those that were adjusted to represent plant codon usage [32]. It has been demonstrated recently that codon optimization may occasionally have an impact on the mRNA structural patterns required for efficient protein production. A deeper comprehension of codon usage and tRNA pool sizes in the source and host species can also help to create codon-harmonized sequences for improved translational efficiency [5].

2.2.4 Suppression of endogenous proteins

Depleting the pool of endogenous seed storage proteins can increase (2–10 fold) the yield of r-proteins by reducing competition for translation, folding, and assembly in the endoplasmic reticulum. E.g. The production of r-proteins, such as cedar pollen allergen, was enhanced by decreasing the 13-kDa prolamin pool in rice endosperm by proteome rebalancing [33]. RNAi or the application of expression hosts with traditionally produced mutations in storage protein genes have been the usual methods used thus far to decrease natural seed storage proteins in PMF applications [34,35]. Targeting storage protein genes in sorghum, camelina, and wheat has been done using CRISPR/Cas9 [36,37]. It is possible to generate seed crops deficient for endogenous storage proteins through genome editing as hosts for PMF production, as their phenotype is deemed stable and they lack RNAi constructions, which lowers the possibility of transgene cassette interference.

2.2.5 Metabolic engineering

Tobacco and other non-food/feed plants lessen the chance of product contamination in the food/feed chain. Still, some plants are unsafe since they can yield harmful substances, like the tobacco plant's alkaloid nicotine. Biopharmaceutical products must undergo purification procedures to guarantee the removal of tiny molecules and protein-based contaminants, lowering their limit of detection [5]. Therefore, it makes sense to develop a PMF chassis free of such potentially harmful substances. This objective has been accomplished in tobacco by deleting both alleles of each of the six genes that code for berberine bridge enzyme-like (BBL) proteins, which carry out the last oxidation process in the formation of nicotine. This method involved the use of CRISPR/Cas9, which led to 99.6 % lower nicotine levels. However, if important enzymes are targeted during secondary metabolism modulation, this could have unintended side effects [38]. Metabolite levels can be spatiotemporally adjusted by targeting relevant transcription factors, rather than directly modifying enzyme expression through gene deletion or overexpression [39]. Compared to transgenic silencing, transient silencing of CysP6 was shown to be a more effective method, as evidenced by a rise in the accumulation of the target r-protein, interleukin (IL)-10, in plants. Attempts to inhibit protease degradation in suspension cultures of cell lines that produce the 2F5 antibody resulted in a reduction in protease degradation and an increase in antibody accumulation. Proteases can be successfully silenced via RNAi; alternatively, plant-derived protease inhibitors, like cystatins and cysteine protease inhibitors, can be co-expressed [40,41].

2.2.6 Cellular level modification

The creation of structurally specified glycans remains a difficult problem despite their recognized significance for r-proteins. However, a better knowledge of glycosylation pathways, current developments in analytical techniques, deconstructed vectors, targeted genome editing, and developing approaches for subcellular localization employing chimeric glycosyltransferases (GTFs) are assisting in the logical design of unique glycan biosynthesis paths. Plants are widely employed for the manufacture of r-proteins because they are especially open to glycoengineering techniques [42]. One of the most important post-translational modifications (PTMs) is glycosylation, which is essential for the clinical efficacy of several pharmacological proteins, including vaccine antigens and antibodies [43]. A range of homogenous human-type glycoforms has been synthesized in planta using four main methods. First, the removal of plant-specific enzymes that produce non-human glycan structures. The second is the appearance of mammalian GTFs and supporting proteins. Thirdly, optimizing the subcellular localization of glycosylation processes. Finally, there is the utilization of multigene vectors that are transiently expressed [44]. With significant effort, human-type glycosylation pathways have been introduced into plants to replace plant-specific glycan systems, and these glycoengineered plants can now produce human-like glycoproteins. In recent decades, promising glycoengineering techniques have made it feasible to humanize plant N-glycosylation, either by de novo creation of heterologous GTFs that are comparable to those found in humans or by inactivating the host plant's Indigenous GTFs [45]. Another approach of non-immunogenic glycosylation, based on RNA interference, regulates the amounts of fucosyl glycans and xylosyl and stops the addition of undesired residual sugars to biotherapeutic proteins [9]. By eliminating plant-specific glycan processing events and engineering glycosylation pathways, researchers were able to achieve the production of viral glycoproteins with glycan structures that closely resembled those found on native viral proteins. This glycan engineering approach aimed to enhance the immunogenicity and efficacy of recombinant viral glycoprotein vaccines by ensuring that the glycosylation patterns mimicked those of the wild-type virus [46]. Glycoengineering successful knockout of two β(1,2)-xylosyltransferase and four α(1,3)-fucosyltransferase genes in Nicotiana tabacum cv. SR-1 using CRISPR/Cas9 technology. This genetic modification led to the generation of NtFX-KO lines with altered N-glycosylation patterns, specifically reducing the presence of core α(1,3)-fucose on N-glycans. The engineered plants exhibited improved glycan profiles with primarily GnGn N-glycans, which are more similar to human-like glycosylation patterns [47]. The production of complex protein-based pharmaceuticals in PMF is optimized by glycoengineering, ensuring that proper protein folding, functionality, and safety for human use are achieved. Human-like N-glycan structures are produced in plants through glycoengineering, allowing for the enhancement of protein functionality, the reduction of immunogenicity, and the stabilization of recombinant proteins and peptides to prevent proteolytic degradation and improve overall yield and quality of the final product [29].

2.2.7 Cell culture system for production of recombinant product

Since their introduction in 1902, suspension culture methods have a rich history. They are frequently used in the field of plant biotechnology as an easy-to-use tool for producing r-proteins, secondary metabolites, and other medicinal components on a massive scale. Numerous instances of plant suspension culture have been documented; proteins obtained through this technique comprise the anti-tumor necrosis factor antibodies, human glucocerebrosidase, Newcastle disease virus's HN protein, and recombinant α-galactosidase-A. The choice of host plant, form of plant material (e.g., callus or hairy root), components of the media, type of bioreactor, and operating technique are all crucial elements to optimize when it comes to suspension culture [48,49]. The development of large-scale manufacturing processes depends on the proper functioning of bioreactors. Air-lift reactors, bench-top bioreactors, membrane reactors, bubble column reactors, single-use bubble column reactors, rotating drum reactors, stirred tank reactors, wave and undertow reactors, and wave reactors are among the several types of bioreactors. Their volumetric productivity varies overall between 4.5 and 7.7 mg/L and 100–247 mg/L [50]. Scaled-up automatic micropropagation of huge quantities of shoot biomass under standardized conditions is possible with temporary immersion bioreactors, which periodically submerge biomass in liquid media. Using this approach, the yield of Borrelia burgdorferi (OspA) outer surface protein A was 108 mg/L (7.6 % TSP) [51], and fragment C of tetanus toxin accumulated to around 95 mg/L (8 % TSP) [52]. Another effective method for creating recombinant proteins is an air-lift type bioreactor, which produces the B subunit of the heat-labile toxin produced by E. coli, which accumulated to 0.36 % TSP in Siberian ginseng somatic embryos [53]. The first plant-produced, commercially available therapeutic protein was created in carrot cells cultured in a flexible, disposable bioreactor made of polyethylene, which is the most remarkable accomplishment to date for a tank bioreactor system [54]. Because of their affordability, adaptability, and safety, disposable bioreactor systems like stirred tank reactors or wave-mixed bioreactors have gained popularity in the biomanufacturing sector as a substitute for stainless steel bioreactors, which are used for mammalian cell cultures.

3 Plant species for producing recombinant products

The expression of r-proteins has been achieved through the use of over 100 plant species, tobacco offers one of the best possibilities for the commercial production of r-protein because it has an extended record of success as a crop platform in MF [55]. The well-established technique for transgenic and expression, high biomass yield, presence of a vast processing network, defective RNA silencing, and prolific seed production are the main benefits of tobacco. There is minimal chance that tobacco material will infect the food or feed chains. Because tobacco is not a food or feed crop [56]. Lettuce and lucerne are among the green vegetation being studied for MF. Due to its high dry biomass production per area and ability to be harvested up to 9 times a year, lucerne is very beneficial. Recombinant antibodies have been produced from both lucerne and lettuce. Additionally, lettuce has been looked into as a potential host for recombinant edible vaccine production [57]. r-proteins are fragile when synthesized in an aqueous environment, which leads to decreased yields in leafy crops, which is one of their biggest drawbacks. To extract adequate quantities of the product, the leaves must be processed promptly after harvest or dried or frozen for transportation [56]. Contrary to greens, as a result of seeds having the ideal biochemical conditions to encourage reliable protein accumulation, seeds may be stored for a prolonged period, even at ambient temperatures. Additionally, cereal seeds don't contain the phenolic substances found in tobacco leaves, which increases the effectiveness of the subsequent processing. Several legumes (soybean and pea) and cereals (wheat, rice, and maize) have been demonstrated for seed-based production of r-proteins [55]. A significant benefit of protein expression in vegetable and fruit crops is the potential of the edible parts to be used for the development of nutraceuticals, topical antibodies, and recombinant vaccines. These products can be produced from edible parts, which can be eaten raw, uncooked, or with a bit of processing. At least 3 clinical studies conducted for vaccines were produced from potato tubers, and transgenic potatoes have been used for the production of human milk, antibodies fusion proteins, and glucanases [58]. In addition to having a higher palatability than potatoes, tomatoes also have additional benefits such as a high biomass output and the ability to be grown in greenhouses for better containment. Bananas provide appealing delivery vehicles for edible vaccines, due to their widespread cultivation and consumption by both adults and children [59].

Transgenic trees have also been explored as potential platforms for producing r-proteins. Trees such as poplar and eucalyptus have been genetically engineered to express valuable proteins for various applications [60]. These transgenic trees offer advantages such as high biomass production, long-term protein expression, and the potential for large-scale production of r-proteins [61]. Pulses, which include crops like chickpeas, lentils, and beans, have not been extensively studied for r-protein production compared to other plant species. However, pulses have the potential to serve as alternative platforms for MF due to their nutritional value, ease of cultivation, and genetic tractability. Further research is needed to explore the feasibility of using pulses as hosts for producing r-proteins [60]. Oilseed plants, such as safflower, rapeseed, and sunflower, have been utilized for producing r-proteins due to their high protein content and ease of purification. These oilseed plants offer advantages such as high protein yield, self-pollination, and simplicity in protein extraction [62]. Researchers have successfully expressed pharmaceutical proteins in oilseed plants, demonstrating their potential as efficient bioreactors for MF [61].

4 Exploring the potential of plants in biopharmaceutical manufacturing

Biopharmaceuticals offer several benefits. For instance, they rarely result in the negative impacts connected with traditional small-molecule therapies since they selectively target molecules. Biopharmaceuticals also show great selectivity and activity in comparison to conventional therapeutics [63]. Recombinant human insulin made from bacteria was the earliest pharmaceutical product to be developed for the market in 1982 [64]. Following the expression of interferon, mAb, serum albumin, and hGH fusion protein, the potential of plants for pharmaceutical manufacture was quickly demonstrated. Since then, there have been several examples of pharmaceuticals manufactured from plants, which are listed under the three major therapeutic groups: Some of the most obvious examples are vaccines, antibodies, and other medications.

4.1 Revolutionizing healthcare: transgenic plant vaccines

The discovery of vaccines was a significant accomplishment of the 19th century, and the smallpox vaccine was the first to be developed. The use of vaccinations helped to stop the outspread of epidemic diseases like tetanus, diphtheria, rubella, mumps, polio, hepatitis, and measles [65]. The health of people and animals is now seriously threatened by new infectious diseases. However, using currently available vaccinations is a successful way of stopping the spread of these diseases. Vaccines have evolved from bacterial vaccines to subunit, RNA, and DNA vaccines with the growth of biotechnology, yet these products are challenging to market due to the high cost of production. Most vaccines that are now available on the market are expensive because they require fermenters, extensive production procedures, and expensive technology for purification. Additionally, costs for the formulation, cold storage, transportation, and sterile delivery are incurred [66]. On the other hand, plants offer a cost-effective platform for the development of inexpensive vaccinations. Transgenic plant-derived vaccines have several benefits over conventional injectable vaccines, along with a wide spectrum of potential expressed epitopes, low cost, massive cultivation of biomass, and ease of transportation and preservation [67].

Genetically altered plant vaccine research has advanced for more than 20 years. There have been several effects in the studies of plant-derived medicines and vaccines for people and animals [32] since the development of hGH in transgenic tobacco. Purifying and isolating the r-proteins generated in plant tissue enables the progress of transgenic plant vaccines. The transgenic antigen purified and isolated from plants can produce particular antibodies in animals [68]. As an alternative, the r-protein could be produced in plants' edible parts without further processing for ingestion [69]. The use of edible plants that express heterologous antigens eliminates the need for the recombinant product to be extracted and purified, and the biomolecule is guarded by an outer membrane for increased and sustained activity on mucosal surfaces [70].

Transgenic potato tubers and lettuce leaves that expressed the Hepatitis B virus (HBV) surface antigen (HBsAg) were the earliest plant-produced vaccine candidates to undergo clinical trials [71]. Recombinant vaccines can be developed using a tobacco plant efficiently and economically. Influenza (Flu) vaccine obtained from the Nicotiana benthamiana was transfected with a weakened plant viral vector that expressed influenza haemagglutinin (HAs) genes to produce virus-like particles (VLP) [72]. Medicago Inc. created a highly engineered VP form of vaccine candidate against influenza that contains a plant leader peptide with a C-terminal heterologous transmembrane domine. The vaccine was approved by the FDA after clinical trials verified its efficacy and safety [73]. The heavy chain-GP1 fusion protein (H2GP1) was co-expressed with the light chain (K3) to create an Ebola immune complex (EIC). An EIC was created using a geminiviral replicon system in N. benthamiana. Humanized 6D8 IgG mAb was bound to the C-terminus of the heavy chain (H-chain) of the Ebola glycoprotein, which fused exclusively to a GP1 linear epitope. These findings contribute to an EIC expressed in plants that had good potential as a human vaccination [74]. The development of recombinant antigen (r-antigen) for foot and mouth disease virus (FMDV) by the FMDV VP1 gene constructed with the chloroplast expression vector and introduced to tobacco by gene gun method was already reported [75]. Dengue virus E glycoprotein domain III (EIII) is immunogenic and able to trigger the production of antibodies that can neutralize it. A DNA region coding EIII was transferred into Nicotiana tabacum plant cells. The efficacy of adopting plant-based vaccines to guard against dengue virus infection is demonstrated by the development of domain III of EIII in transgenic tobacco [76]. Pollet et al. [77] investigated that the receptor binding domain (RBD) gene integrated into N. benthamiana produced the spick (S) protein of SARS-CoV-2. Tobacco plants have been genetically altered to produce the extracellular region of the HAs proteins from the H5N1 avian influenza virus opening the way to cheaper and cost-effective vaccine development options [78].

MF has played a minimal role in preventing MERS and SARS, from reaching a critical pandemic level, large-scale response is in the offing. However, the SARS-CoV S-protein's ectodomain was produced in tomatoes, tobacco, and lettuce and was often shown to be immunogenic [79]. Additionally, N. benthamiana was employed to transiently express the SARS-CoV nucleocapsid and membrane protein, giving further proof of immunogenicity [80]. Recently, Ghorbani et al. [81] experimented with an immunoinformatic technique to predict the VLP of SARS-CoV-2 epitopes that were exposed to HBcAg to produce a vaccine against SARS-CoV. The chloroplasts of transplastomic tobacco plants as well as the cytosol of transgenics as evidence suggesting the potential development of an oral vaccination against the SARS-CoV. The viral antigen expressed in transformed plants effectively responded to serum and mucosal immunity as well as used for serological antibody detection tests [82]. Charland et al. [83] produced a potential coronavirus VLP (CoVLP) vaccine made in plants that exhibit the SARS-CoV-2 S-protein and coupled with AS03 was taken into use in the preliminary evaluation of phase 2 of Phase 2/3 clinical trials. Shanmugaraj et al. [84] demonstrated that the Baiya SARS-CoV-2 Vax 1 subunit proteins, which were created via the fusion of the SARS-CoV-2 RBD to the human IgG1 Fc domain (RBD-Fc), developed in N. benthamiana, and coupled with alum, created strong immune responses in both cynomolgus monkeys and mice [85]. Margolin et al. [86] investigated how to make a soluble plant-derived SARS-CoV-2 spike that included the ectopic glycoprotein, this was transiently expressed in N. benthamiana, which greatly improved the accumulation of the glycoprotein (GP). Affordable and reliable manufacturing platforms will increase the availability of vaccinations in countries with limited resources and a large volume of vaccine manufacture is urgently needed. Plant species that provide such platforms to efficiently produce vaccines were described in several research [87]. In immunized hamsters, the N. benthamiana produced antigen developed neutralizing antibodies against both the identical Wuhan and heterologous SARS-CoV-2 delta variants, however, titres were reduced compared to those promoted by the comparator mammalian antigen [87]. Health Canada authorized Covifenz, the first SARS-CoV-2 vaccine made from plants (Tobacco, potato, and N. benthamiana), in 2022 [88].

The transgenic maize with the rabies virus G gene expressed in five putative lines and administrated various doses of G protein through oral delivery in sheep responded productively [89]. Zhang et al. [90] developed an effective oral vaccine, that enhanced the expression of recombinant Norwalk virus (rNV) VLPs in transient tomato plants. It produced elevated levels of (approximately 26.6 μg/g of dry fruit) rNV proteins than previously reported rNV production in potato/tobacco plants [91]. Similarly, Norwalk virus (NV) VLP was obtained from transfected N. benthamiana immunized against the NV [92]. The pBRSAg expression vector constructed with the HBsAg gene was transfected into tomato. The transformed tomato plants produced surface antigen for HBV and this was the first reported plant vaccine for HBV [93]. The most frequent cause of extreme diarrhea in juvenile people is rotaviruses (RV), which are thought to account for close to one million fatalities per year globally in past decades. Wu et al. [94] the study revealed that even after the incorporation of the G1 VP7 gene cloned with PB1131 expression vector was transferred into the potato genome, RV glycoprotein VP7 might still maintain its ability to prevent RV is a challenge. IgG levels were induced by the VP7 DNA vaccine in mice that can't protect from RV. However, mice that were vaccinated with the transgenic tubers produced mucosal IgA and serum IgG antibodies that were specific for VP7. RV might be neutralized by IgA, according to neutralizing tests. These findings suggest that edible RV vaccines might be produced and delivered by plants. Transgenic potato tubers and lettuce leaves expressing the HBsAg [95], maize and potato transgenic lines produced the enterotoxigenic E. Coli labile toxin B- subunit [96], transgenic potatoes expressing the NV capsid protein (CP) [97], and virus-introduced spinach producing rabies virus GP [98] were the first vaccine candidates produced from plants to enter clinical progress. The need for a Zika viral (ZIKV) vaccine is urgent given the current global outbreak of the virus and its associated neurological problems in adults, microcephaly in fetuses and infants, and other birth defects. As a result, Yang et al. [99] created a vaccine subunit based on the ZIKV envelope E (zE) protein and studied the immunogenicity of the vaccine in mice. zE quickly increased in N. benthamiana plant leaves because of transient expression. Biochemical testing demonstrated a range of mAbs that detect different zE conformational epitopes specifically bound to plant-produced zE (PzE), according to the results of the testing. Given that two dosages of PzE caused potent zE-specific antibodies and cellular immunological activities in mice, it has been shown that PzE is highly immunogenic.

Ward et al. [100] provided results from two phase III efficacy trials of a plant-produced recombinant quadrivalent virus-like particle (QVLP) influenza vaccine, one in adults aged 18–64 years, and the other in older individuals aged 65 years and over. With the use of this platform, which relies on the transient expression of proteins in the plant N. benthamiana, VLPs containing HAs protein trimers may be produced, which can then be joined to create a QVLP vaccination [101]. In both pre-clinical and clinical tests, it has been found that influenza HAs-containing plant-derived VLP vaccines elicit potent CD4+ T and humoral responses. These insights could contribute to an explanation of the vast and cross-reactive immune responses induced by plant-based vaccinations [102]. Jeshvaghani et al. [103] examined the oral immunogenicity of a synthetic r-protein (SICL) including LtB, CfaB, StxB, and Intimin. Serum IgA and fecal IgG antibody responses were produced after the oral vaccination of mice. These findings showed that the fusion r-protein SICL in canola transgenic seed functions as a potent immunogen, inducing both mucosal and systemic immunogenicity as well as defense against ETEC and EHEC toxicity. A malarial candidate vaccine produced through plants (N. benthamiana) based on Pfs25 has been created as a chimeric non-enveloped VLP that combines Pfs25 with the CP of the alfalfa mosaic virus. However, the vaccination did produce dose-dependent Pfs25-specific IgG in vaccinated individuals [104]. The cytoskeletal VP1 of the FMDV expressed in transgenic Stylosanthes guianensis cv. Reyan II has been used to design a new oral vaccination method for the protection of FMDV [105].

Plastid transformation has successfully been used to express vaccination antigens. Yácono et al. [106] investigated chloroplast-mediated production of the anti-GRA4 for Toxoplasma gondii in tobacco plants and assessed the cellular and humoral response and level of protection following oral delivery of chlGRA4 in a mouse model. Mice that were administered with an oral dose of the chlGRA4 vaccine had 59 % fewer brain cysts than control mice. A mucosal immunity of the chlGRA4 vaccine was described by the development of specific IgA, and a systemic immunological response was characterized by the creation of GRA4-specific serum antibodies and the production of IL-4 and 10, and IFN-c by splenocytes. These findings show that oral delivery of chlGRA4 encourages the Th1/Th2 responses, which regulate Toxoplasma infection. In transgenic Solanum lycopersicum hairy roots, the expression of an r-protein, which comprised the ricin toxin B chain and the rabies glycoprotein (rgp-rtxB) fusion antigen, was controlled by a constitutive CaMV35S promoter. Following intra-mucosal immunization, the partially refined RGP-RTXB chimeric protein successfully induced an immune response in BALB/c mice [107]. A tobacco mosaic viral transient expression system was used to create a plant-optimized gene expressing Narita 104 virus (NaV) CP in N. benthamiana. At 4 days following infection, NaVCP had accumulated to a maximum of around 0.3 mg/g of fresh leaf weight [108]. The parallel expression of four different proteins in different concentrations was used to prevent the Bluetongue virus (BTV), which has a negative influence on the livestock trade due to its high death rates in ruminants. Thuenemann et al. [109] revealed that VLPs generated and constructed in N. benthamiana utilizing the cowpea mosaic virus-based HyperTrans (CPMV-HT) and related pEAQ transient expression system induced a potent antibody response in sheep.

There are multiple existing clinical studies employing purified antigens, produced rapidly in vaccine particles from tobacco plants. For instance, a phase II clinical investigation taken on a flu QVLP created from plants (N. benthamiana) was accomplished, and it was newly reported that phase III clinical research is underway [101]. The current status of research on plant-based vaccines against viruses is quite promising. Recent advancements have demonstrated the efficacy of PMF in producing viral vaccines and therapies. Notable progress includes the successful use of plant-made antigens and mAbs for treating animal and human viral diseases. HAC1, an N. benthamiana -produced recombinant HAs flu vaccine created by Fraunhofer USA Center for Molecular Biotechnology (FhCMB) for the treatment of a disease caused by a new H1N1, phase 1 trial was evaluated for safety and immunogenicity first-in-human. In less than a month, FhCMB designed, developed, and manufactured HAC1, and then scaled it up for current Good Manufacturing Practices in FhCMB's pilot plant [110]. Also plant recombinant HAs protein was examined in phase I human trial against H5N1 influenza stain [111]. The 6-g dose of MucoRice-cholera toxin (CTB) vaccination produced cross-reactive antigen-specific antibodies against the B subunit of CTB and E. coli heat-labile enterotoxin without causing significant side effects, according to a phase I study presented by Yuki et al. [112]. The study presented a phase I trial that was double-blind, randomized, and placebo-controlled, demonstrating that oral MucoRice-CTB induces neutralizing antibodies against CTB regardless of ethnicity. Despite advancements in subunit vaccines through transient expression techniques, no plant-derived recombinant vaccine has received approval for human use to date [112]. The successful expression of plant-based vaccine candidates is presented in Table 2. The lack of plant-based vaccines can be attributed to several key hurdles that need to be addressed. Firstly, navigating the complex regulatory landscape poses a significant challenge, as these vaccines must meet stringent criteria for safety, efficacy, and environmental impact to gain approval. Additionally, the commercialization process of plant-made vaccines involves a multitude of steps and collaborations across different groups, requiring careful consideration of factors such as business planning, financing, and regulatory compliance before significant investments are made. There is also a notable knowledge gap between the laboratory research phase and the commercialization phase, highlighting the need for a more seamless transition that encompasses aspects like business planning, financing, and regulatory approval. Cost considerations and low adoption rates among farmers due to the expense and handling requirements of traditional vaccines further hinder the uptake of plant-based alternatives. Environmental concerns surrounding the safety of vaccine-producing plants intended for food or feed crops also present challenges, necessitating strict oversight and production conditions to ensure regulatory compliance. By addressing these hurdles, the development and adoption of plant-based vaccines can be facilitated, offering a promising avenue for more efficient and cost-effective veterinary solutions [113]. To overcome the key hurdles hindering the development and adoption of plant-based vaccines, several strategies can be implemented in the near future. Collaboration with regulatory authorities to streamline approval processes and provide comprehensive data on safety and efficacy is essential. Enhanced partnerships between research institutions, industry players, and regulatory bodies can facilitate knowledge sharing and efficient progression from research to commercialization. Increased investment in research and development of plant-based vaccine technology is crucial to address knowledge gaps and enhance production efficiency [114]. Exploring cost reduction strategies, such as optimizing manufacturing processes and scaling up production, can make plant-based vaccines more economically viable. Educational campaigns to raise awareness among farmers and stakeholders about the benefits and safety of these vaccines can help increase adoption rates. Implementing stringent environmental monitoring and containment measures for vaccine-producing plants is necessary to address safety concerns. Advocating for supportive policies and incentives from government agencies can create a conducive regulatory environment for the development and adoption of plant-based vaccines in the veterinary industry [115]. By systematically implementing these strategies, the future prospects for plant-based vaccines in veterinary medicine can be significantly enhanced, leading to improved animal health, cost-effective solutions, and sustainable agricultural practices.Table 2 Vaccine candidates expressed in plant system.

Table 2Disease/Pathogen	Plant	Expression system	Antigen/Antibody	Reference	
Anthrax	Tobacco	Biolistic Stablea	PA	[197]	
Avian chlamydiosis	Rice	Agrobacterium	MOMP	[198]	
Avian influenza	N. benthamiana, Alfalfa, soybean,
Tobacco, Duckweed		HAs (H7, H5, H6)	[199]	
Bacillus anthracis	Tobacco	Agrobacterium	PA (dIV)	[200]	
B. anthracis	N. benthamiana	Transient	PA	[201]	
Bluetongue virus	Nicotiana benthamiana	Agrobacterium Transient	Bluetongue-VLP	[109]	
Bovine herpes virus	N. benthamiana	Agrobacteriumb	Glycoprotein D	[202]	
BVDV	Alfalfa	Agrobacteriumb	Structural protein E2	[203]	
Brugia malayi	Tobacco	Agrobacterium	Bm ALT-2	[204]	
Cholera	Potato	Agrobacterium	CTB	[205]	
Cholera	Tomato	Agrobacterium	CTB	[206]	
Cholera	Rice, Maize	Particle Bombardment	CTB	[207,208]	
Cottontail rabbit
Papillomavirus	Tobacco	Agrobacteriumb	L1-CP	[209]	
CCHFV	Tobacco	Stable, Transient expression	G1/G2	[210]	
Cysticercosis	Papaya	Particle Bombardment	KETc1, KETc12, KETc7	[211]	
Diarrhea	Medicago sativa		E2	[203]	
E. coli	Potato	Agrobacterium	Enterotoxin B subunit	[212,213]	
E. coli	Maize	Agrobacterium	LT-B	[214]	
E. coli	Rice	Microprojectile Bombardment	Enterotoxin B subunit	[215]	
E. coli	Lettuce	Agrobacterium	LT-B	[216]	
E. coli	Soyabean		LT-B	[217]	
E. coli	Rapeseed		SICL (StxB, Intimin, CfaB, LtB)	[103]	
E. coli	Corn	Agrobacterium	LT-B	[96]	
E. coli	Arabidopsis	Agrobacterium	LT-B	[218]	
E. coli	Alfalfa	Chloroplasta	FaeG	[219]	
E. coli	Carrot	Agrobacteriumb	LT-B	[220]	
Ebola	N. benthamiana	Transient expression	GP1	[74]	
FMDV	Stylosanthes guianensis	Agrobacteriumb	VP1	[105]	
H1N1 (Influenza A)	N. benthamiana		HAC1	[110]	
H3N2	Maize	Agrobacterium	Nucleoprotein	[221]	
H5N1	N. benthamiana	Transient expression	HAs protein	[111]	
H5N1	N. benthamiana	Agrobacterium Transient	HAs protein	[222]	
H5N1 & H1N1	N. benthamiana	Agrobacterium Transient	HAs protein	[223]	
H7N7	N. benthamiana	Agrobacterium Transient	HAs protein	[224]	
HBV	Tobacco	Agrobacteriumb	HBsAg	[225]	
HBV	Banana cv. Rasthali	Agrobacterium	HBsAg	[226]	
HBV	Tobacco	Agrobacterium	HBsAg	[227]	
HBV	Rice	Agrobacterium	HBsAg	[228]	
HBV	Tomato	Electroporation, Agrobacterium	HBsAg	[229,230]	
HBV	Potato		HBsAg	[231]	
HBV	Lettuce	Agrobacterium	S-HBsAg	[232]	
HBV	Maize		HBsAg	[233]	
HBV	Potato	Agrobacteriumb	HBsAg	[234]	
HBV	N. benthamiana	Agrobacteriumb	HBsAg	[235]	
Helicobacter pylori	Carrot	Agrobacterium	UreB (urease B)	[236]	
HIV	Arabidopsis, carrot		HIV-1 p24	[237]	
HIV	Lettuce	Agrobacterium	C4(V3)6	[238]	
HIV	Tobacco	Biolistic transformationa	anti-C4V3	[239]	
HIV type 1	Tobacco	Biolistic Stablea	Pr55gag
Polyprotein	[240,241]	
HIV-1	Tobacco		p24-Nef	[242]	
HPV	Tomato		HPVL1-E6/E7	[243]	
HPV	Tobacco	Agrobacteriumb	L1-CP	[244]	
HPV	Tobacco		HPV16-L1	[245]	
IBV	Potato	Agrobacteriumb	S protein	[246]	
IBDV	Rice	Agrobacteriumb	VP2	[247]	
Influenza	N. benthamiana	Agrobacterium Transient	HAs protein	[248]	
Influenza		Agrobacterium	QVLP	[100,249]	
Japanese encephalitis virus	Rice	Agrobacterium	E protein	[250]	
Japanese encephalitis virus	Nipponbare	Agrobacteriumb	Envelope protein (E)	[250]	
Malaria	N. benthamiana		Pfs25-VLP	[104]	
Mycobacterium tuberculosis	Carrot		ESAT6, CFP10	[251]	
Mycobacterium tuberculosis	Tobacco, Lettuce	Chloroplast expressiona	ESAT6, Mtb72F, Mtb32	[252]	
Narita 104 virus	Nicotiana benthamiana	Agrobacterium Transient	NaV-VLP	[108]	
NDV	N. benthamiana		HN protein	[253]	
NDV	Maize	Biolistic Stablea	Fusion (F) protein	[254]	
NDV	Tobacco	Agrobacterium	GST–HN	[255]	
Norwalk virus	Tobacco, Potato	Agrobacterium	rNV-CP	[91]	
Norwalk virus	N. benthamiana	Agrobacteriumb	CP	[256]	
Norwalk virus	Tomato		rNV	[90]	
Norwalk virus	N. benthamiana	Agrobacterium	rNV	[256]	
Plasmodium falciparum	Tobacco/Lettuce		AMA1a	[257]	
P. falciparum	Tobacco/Lettuce		MSP1a	[257]	
Poliovirus	Tobacco		VP 1	[258]	
PRRSV	Arabidopsis	Agrobacteriumb	Glycoprotein	[68]	
RHDV	Tobacco	Agrobacteriumb	VP60	[259]	
Rabies	Maize	Biolistics	G protein	[89]	
Rabies	Tomato		RGP–RTB	[107]	
Rabies	Tobacco	Agroinfiltration	N protein	[260]	
Rinderpest virus	Peanut	Agrobacteriumb	HAs protein	[261]	
Rotavirus	M. sativa		VP6	[262]	
SARS-CoV	Tomato, Tobacco	Agrobacterium	S1 protein	[82,263]	
SARS-CoV	N. benthamiana	Agrobacterium	SARS-CoV nucleo-capsid	[264]	
SARS-CoV, SARS-CoV-2	Cowpea		VLPs	[265]	
SARS-CoV-2	N. benthamiana		S Protein	[266,267]	
SARS-CoV-2	Tobacco	Transient	S glycoprotein	[268]	
SARS-CoV-2	N. benthamiana	Transient	RBD-Fc	[84]	
Tetanus/Clostridium tetani	Tobacco	Chloroplast expressiona	TetC	[89]	
T. gondii	Tobacco	Biolistic transformationa	GRA4 antigen	[106]	
T. gondii	Tobacco		SAG1	[269]	
TGEV	Tobacco	Agrobacteriumb	S protein	[270]	
TGEV	Maize	Agrobacteriumb	S protein	[271]	
Vibrio cholerae	Tobacco	Biolistic transformationa	CTB-GFP	[272]	
V. cholerae	Rice		CTB	[112]	
V. cholerae, E. coli	Tobacco	a	LTB, CTB	[273]	
Yersinia pestis	Tomato	Transient	F1-V	[274]	
Y. pestis			F1-V fusion antigena	[275]	
Zika virus	N. benthamiana	Transient expression	zE	[99]	
a Chloroplast transformation.

b Stable Transformation.

4.2 Plantibodies: the future of antibody therapeutics

The adaptive immune system of animals creates glycoproteins called antibodies. They have high specificity and affinity for recognizing and binding specific target antigens, which enables them to eliminate pathogens and other foreign substances from the body [116]. There are five kinds of immunoglobulins produced by mammals, each having a unique Fc (fragment crystallizable) region and corresponding effector function (IgA, IgD, IgE, IgG, and IgM). IgG is the predominant serum antibody in mammals [117]. Immunotherapy has tremendous results for diseases that were previously thought to be incurable with the effective therapeutic mAbs now being developed [118]. The mAbs are the primary type of biopharmaceutical products at present. However, they are generally utilized to treat certain diseases that each have relatively low occurrences [119]. Around 1990, the term "plantibody" was introduced to describe plants as possible hosts for producing antibodies [120]. Plants cannot natively produce antibodies, but by adding the relevant immunoglobulin genes, they may be made to do so [121]. Therefore, two genes - one each for the light and H-chains are required for the development of a full-size IgG in plants. While a secretory immunoglobulin A (sIgA) expression needs four genes, one for each of its elements [116]. Plantibodies were produced by the following methods, Conventional method [122]; In vitro cell and tissue culture [123]; Breeding and sexual crossing [124]; and Transgenic seeds [125].

Porphyromonas gingivalis has a structural subunit Fimbrial protein fimbrillin (FimA) has been recommended as a candidate vaccine to reduce periodontitis induced by P. gingivalis [126]. Choi et al. [126] investigated the biological functions of the FimA-specific mAb created in the plant (anti-FimA plantibody) suppressed in vivo/in vitro. P. gingivalis infections of periodontal ligament cells. In comparison to the death of bacterial cells with extraneous IgG, mouse macrophages opsonized with the anti-FimA mAb dramatically improved the intracellular killing of P. gingivalis. Protein microbicides against HIV can aid in preventing infection if they are administered in high and frequent doses leading to high prices [126]. Plants are useful as manufacturing platforms because they provide secure, affordable, and scalable substitutions, which would make it possible to create therapeutic proteins on a budget and in large quantities [127]. Wide-ranging HIV neutralization activity is observed in human mAb 2G12. The 2G12 production has widely been delineated in various plants [128]. Vamvaka et al. [127] described the production of transgenic rice plants that express the HIV-neutralizing mAb 2G12 in the endosperm, The H-chain was largely glycosylated for an antibody whereas the heavy and light chains combined to form effective antibodies with stronger HIV-neutralizing activity was observed. Recently, a transient expression approach was used in N. benthamiana to produce a novel anti-HIV-1 bispecific bNAb-lectin fusion protein [129], Macaques [130], and rice endosperm [131]. The system's potential for molecular farming was evaluated by developing doubled haploid transgenic barley that was designed to produce r-protein around 160 μg per g grain of the anti-HIV-1 mAb 2G12. In accordance with its vacuolar localization, the r-protein was observed close to the edges of protein bodies as a combination of different N-glycans [132].

Recombinant mucosal antibodies are promising molecular targets for the design of next-gen biotherapeutics for the prevention of several serious diseases through passive immunizations and the treatment of mucosal antibody deficits in patients [133]. IgA is a potential oral passive immunization antibody against mucosal bacteria like E. coli that produces the Shiga toxin [134]. Nakanishi et al. [134] developed cDNA that encodes an anti-Stx1 antibody, and all the H-chain constant regions and variable regions were taken from a mouse IgA mAb. They used a plant expression system to generate the cDNA to produce enough IgA at a reasonable cost in consideration of oral delivery. The effective expression of sIgA and sIgM in diverse antibody formats in a diverse of plants, including tobacco, maize, tomato, and its close relatives N. benthamiana, and A. thaliana, demonstrates that plant cells are capable of producing high-quality mucosal antibodies [133]. Loos et al. [135] presented a comparison of two mAbs (HA78 and 2G12 against Hepatitis A and HIV respectively), expressed in wild-type (WT) seeds of Arabidopsis plants and glycosylation mutants missing plant-specific N-glycan residues. The epitope specificity or neutralization activity of HIV-neutralizing antibody 4E10 and the human tumor-specific antibody M12 was analyzed as a potential reason for the yields developed in N. benthamiana [136]. Three anti-Ebola chimeric mAbs were produced in N. benthamiana. This pilot experiment results showed the successful postexposure efficiency of mAb produced from N. benthamiana [137]. Additionally, the development and testing of vaccines like ZMapp for Ebolavirus infection showcase the potential of plant-based approaches in combating viral infections [138]. ZMapp is composed of three distinct mAbs, each specifically designed to target the Ebola virus. The ZMapp vector contains genes (MB-003, 1H3, and 13C6) that encode these three antibodies. The Ebola virus is effectively neutralized by a combination of three antibodies that are generated in tobacco plants utilizing a plant-based expression approach [139,140]. The study assessed the viability of using a plant expression approach to create the B38 and H4 human anti-SARS-CoV-2 mAbs quickly which were recently found to be clinically useful. By employing a plant expression geminiviral vector to selectively co-express the light and heavy-chain sequences of both antibodies, it was able to rapidly accumulate formed mAbs in N. benthamiana leaves four days after infiltration [141].

The development of transgenic tomato plants that express recombinant human IgA, targeted against the VP8 peptide of the SA11 RV strain. The fruit of the modified plants contained 3.6 % of the total soluble protein as IgA. In an in vitro viral neutralizing study, negligibly processed fruit-derived products fit for oral consumption showed anti-VP8 binding activity and substantially suppressed viral infection [142]. Utilization of recombinant sIgA complexes potentially increases antibody-based passive immunomodulatory strategies for treating a variety of mucosal infections [143]. The broad neutralizing anti-HIV mAb 2G12 was expressed, purified, and characterized using transgenic tobacco and transient N. benthamiana. Heterodecameric complexes were generated and accumulated in vacuoles and other intracellular spaces within leaf tissue. The antibody yield in transgenic tobacco reached 15.2 mg/g of leaf fresh mass (LFM) and increased to 25 mg/g LFM with the transient system. Transgenic tobacco demonstrated superior sIgA complex assembly. The protein L purified antibody exhibited precise binding to HIV gp140 and effectively neutralized HIV 2 and 3 isolates [144]. Compared to animal-produced antibodies, these are less expensive, safer to use, and simpler to handle [145]. The production cost of 1 g mAb in transgenic plants is anticipated to be around 0.10 USD [119], which is far less than the usual cost of 53–106 USD per g of CHO cell production [145]. Safety issues and handling of antibodies produced in plants are critical considerations in the development of plant-based pharmaceuticals. A comprehensive risk assessment for viral safety is conducted, evaluating factors like raw materials, operators, process aids, equipment/utilities, and environmental conditions. Quality control measures are implemented throughout the production process, including the use of certified raw materials, operations in controlled environments, and virus removal steps like nanofiltration [146]. In the first-in-human phase I clinical trial, the primary focus is on evaluating the safety and reactogenicity of the plant-derived mAbs when administered intravaginally. Regulatory compliance is paramount, with the project following guidelines to ensure adherence to standards. Future research is needed to further characterize the pharmacokinetic properties of plant-derived antibodies and monitor their safety and efficacy. These efforts underscore the importance of stringent safety assessments, quality control, and regulatory compliance in the production and handling of antibodies derived from plants [128].

An alphavirus transmitted through mosquitoes named the chikungunya virus (CHIKV) can infect people and lead to chronic, severe arthritis. There aren't any approved medicines or vaccines for treating CHIKV infections in humans at the moment. The potential for treating CHIKV in an animal model utilizing anti-CHIKV mAbs generated in glycoengineered (ΔXFT) and Wild type (WT) N. benthamiana was examined by Hurtado et al. [147]. Strong in vitro neutralizing activity against CHIKV was shown for both ΔXFT and WT plant-produced mAbs. Notably, both mAb glycoforms exhibited in vivo effectiveness in test models, with the mAbs produced by the ΔXFT exhibiting slightly greater efficacy [147]. Politch et al. [148] performed a phase I trial in a multipurpose preventive technology (MPT) product called MB66 film, containing mAbs against HSV-1, 2, and HIV-1. N. benthamiana was used to produce the mAbs by the transient system. According to the observations of this MB66 Phase I clinical trial, both single and repeated vaginal applications of a mAbs film against various HIV and HSV, which had been made using a quick, economical plant-based system, were well tolerated and safe. The film also delivered antibody concentrations in vaginal secretions that were able to neutralize HSV-2 and HIV-1 for a minimum of 24 h succeeding film application. As a result, plantibodies are now widely employed in the medical, veterinary, and other fields of commercial activity. They are utilized to treat malignancies, inflammatory diseases, and immunological disorders [148]. Clinical studies are now being conducted on many plant-produced antibodies. Reported plantibody production in plant systems is presented in Table 3.Table 3 MF system for antibody production in plants.

Table 3Plantibody	Antigen	Host	Mechanism	Reference	
anti-FimA	FimA	Rice cell suspension	Passive immunization against P. gingivalis	[126]	
B38 and H4	anti-SARS-CoV-2	N. benthamiana	Neutralization activity	[141]	
IgA	anti-streptococcus mutants	Tobacco		[276]	
IgG1		Soybean, rice	Herpes simplex virus	[277]	
IgG		Corn	Respiratory Syncytial Virus	[278]	
mAb 4E10	4E10	N. benthamiana	HIV-neutralizing antibody	[136]	
mAb M12	Tumour specific M12	N. benthamiana	human tumor-specific antibody	[136,279]	
mAbs	P2G12	Tobacco	HIV neutralizing	[128]	
mAbs	HA78	Arabidopsis	Hepatitis A virus	[135]	
mAbs	2G12	Arabidopsis	HIV-neutralizing antibody	[135]	
mAbs	2G12, 2F5	Tobacco, Maize, Rice	HIV-specific antibodies	[127,128,131,280,281]	
mAbs	anti-HIV-1 2G12	Barley	HIV-neutralizing antibody	[132]	
scFv	CLas proteins InvA and TolC	Carrizo	Greening Disease	[282]	
Guy's 13	Streptococcal antigen I or II	Tobacco	Dental caries	[283]	
ScFvT 84.66	Carcinoembryonic antigen	Wheat, Pea
Rice	Cancer treatment	[284,285]	
T84.66	Carcinoembryonic antigen	Tobacco	Cancer treatment	[286]	
CO17-1A	Surface antigen	N. benthamiana	Colon cancer	[4]	
Anti-HSV-2	Herpes simplex virus 2	Soybean	Viral neutralizing	[277]	
anti-HBsAg	HBV	Tobacco	sAg antibody	[287]	
anti-Stx1		Arabidopsis	mAb for E. coli	[134]	
BR55-2 mAb	Anti-Lewis Y	Tobacco		[288]	
cT84.66, scFvT84.66	Anti-cancer	Tobacco		[286]	
H10 mAb	Anti-TNC	Tobacco		[289]	
hIgA_2A1	anti-VP8*	Tomato	Retrovirus neutralizing	[142]	
IgG		Tobacco	Viral neutralizing	[290]	
mAb	anti-CHIKV	N. benthamiana	Neutralizing	[147]	
mAb		N. benthamiana	HIV and HSV neutralization activity	[148]	
mAb	PA	N. benthamiana	neutralize toxin activity of B. anthracis	[291]	
mAb	Anti-PA	N. benthamiana	Anthrax neutralizing	[291]	
mAb BR55-2	Anti-Lewis Y	Tobacco	Cancer neutralizes	[288]	
P2G12 SIgA	anti-HIV	N. benthamiana		[144]	
R12 mAb		Tobacco	Rabies treatment	[292]	
Rabies virus glycoprotein		Tomato	Rabies treatment	[293]	
RIG		Tobacco	Neutralizing	[294]	
scFv	anti-BoNT/A	Tobacco	Immunization against Clostridium botulinum	[295]	
scFv	Anti- Salmonella	Tobacco	Immunization against Salmonella enterica	[296]	
scFv	Anti-BoNT/A	Tobacco	Immunization against Botulism	[295]	
scFv	anti-LPS		Immunization against Salmonella	[296]	
scFv, IgG1, diabody	anti-CEA	Rice, wheat, pea, tomato	Neutralize carcinoembryonic antigen	[297]	
scFvT84.66	Ant-cancer	Oryza sativa, Wheat	Tumour neutralizing	[284,285]	
sIgA	anti-VP8*	N. benthamiana	Retrovirus neutralizing	[298]	
SlgA		Corn	Herpes simplex virus	[299]	
CaroRX		Tobacco	Immunization against Streptococcus mutans	[300]	
VHH-IgG,
VHH-IgA	anti-ETEC	Arabidopsis		[301]	
VHH-Fc		Arabidopsis, N. benthamiana		[302]	
ZMapp		N. benthamiana	Ebola neutralization	[303]	

4.3 MF platforms for protein and enzyme production in plants

MF can be used by plants to produce r-protein products. r-proteins play essential roles in various aspects of our lives, contributing to advancements in healthcare, agriculture, industry, and research. Recombinant enzymes are employed as great-quality proteins for research, therapeutic, and diagnostic purposes, as well as in the chemical and food industries [149]. Recombinant pharmaceutical proteins and industrial enzymes are now increasingly being produced in plants as factories [150]. r-proteins can also be released into the culture media, enabling recovery and ensuing purification since cells retain the majority of the contaminated proteins and can be eliminated from the culture media [151]. In specific, the MF of cell-wall-deconstructing enzymes like hemicellulases, ligninases, xylanases, and cellulases has enormous potential for the biofuel sector concerning the manufacturing of cellulosic ethanol [152]. The hundreds of various proteins in plants were successfully produced including medicinal proteins such as hormones, antibodies, vaccines, and enzymes, along with proteins for cosmetic, research, and diagnostic applications [149]. The earlier studies on MF reveal a diverse landscape characterized by challenges in establishing standardized processes due to the wide range of expression strategies and production systems. Despite the success of traditional biotechnology platforms, versatility is offered by molecular farming for different products and applications. The increasing interest in the downstream processing of plant-made pharmaceuticals is evidenced by a rise in publications and expanding manufacturing capacities [71]. The broad spectrum of species and production techniques working in the plant-based expression of proteins is a unique property [149]. Accordingly, the MF community has started emphasizing a few platforms, with tobacco and its related species N. benthamiana popularly [71]. Animals were commonly used in further studies with therapeutic proteins. For example, the West Nile virus (WNV) envelope protein domain III created in N. benthamiana prevented mice from fatal WNV infections [153], while the transiently developed hepatitis C virus E1E2 heterodimer in lettuce induced immunological activity in mice [154].

These proteins are produced in plants, which has benefits such as authentic plant allergen presentation for allergy detection [155] and lack of contamination with animal-derived components or bacterial endotoxins, which are required for producing GF and cytokines as they are used in food production or animal cell culture [156]. Refined protein is employed as a bioactive component in cosmetic products [157]. Therefore, there has been an abundance of interest in transgenic plants as the bioreactors of a new generation because of their benefits, such as the reliability of recombinant molecules (vaccines, antibodies, r-proteins, GF, enzymes, etc.), and the large-scale execution achieved at low cost [62]. Transgenic plants have emerged as a potential replacement for conventional bioproduction approaches, such as cultured mammalian cells, yeast, and bacteria, for the development of expensive r-proteins for industrial and medicinal sectors [61]. Cathepsin D inhibitor can serve as the structural stabilizer to maintain the targeted r-proteins in the plant cytosols [158], and this signal has shown to be extremely efficient and cost-effective for producing r-protein. The Israeli company Protalix Biotherapeutics develops taliglucerase alfa, a recombinant isoform of human glucocerebrosidase (GCase), in plant suspension cultures [159]. Another version of the recombinant enzyme (imiglucerase) is produced in CHO cells [160]. Although taliglucerase alfa is the only r-protein produced by plants that have received standard clinical permission for pharmaceutical use in humans, several additional medicine candidates have already advanced to late-stage medical trials. For example, Pegunigalsidase alfa has recently begun phase III trials, a recombinant type of human globotriaosylceramide (Gb3) generated in tobacco as an enzyme substitution medication for Fabry disease [161]. A vaccine produced from plants for seasonal influenza haemagglutinin was transiently produced in N. benthamiana to form encapsulated VLPs that mimic WT influenza virions but lack RNA [100]. The driving force behind MF renders its expenses significantly lower than those of traditional farming. One of Franklin and Mayfield's newest production studies interested in the unicellular alga Chlamydomonas reinhardtii. The only plant whose transformation was carried out in all of its genome parts (mitochondria, plastid, and nucleus) is C. reinhardtii [62].

In recent years, human insulin has become the most widely used recombinant biopharmaceutical with large-scale production, with yearly output averaging over 13 tonnes. Future demand for economical insulin is predicted to significantly grow because of the rising prevalence of diabetes and the development of alternative delivery systems that need greater dosages [162]. Current manufacturing methods will struggle to fulfil this demand due to constraints on production efficiency and capacity. New expression and recovery technique enables the production of biopharmaceuticals from oilseeds at low cost [163]. Human recombinant insulin precursor was produced using this approach and expressed in genetically altered plants [163]. In vitro, plant-based insulin can be an enzymatically processed product similar to that of DesB30-insulin, which is estimated to accumulate in considerable quantities in transgenic seed (0.13 % of the total protein in the seed) [164]. Numerous other MF products have been created, many of which are presently undergoing human clinical trials as reviewed by Schillberg and Finnern [149]. Examples of MF expression systems and products such as expansion (enzyme), Biofuel production in transgenic Zea mays seeds [165], Daucus carota produced Elelyso (Enzyme), which is used for Gaucher's disease treatment [166], Artemisinin's derived from Artemisia annua and is well established for the medications of malaria [167]. Some examples of PMF-produced proteins and enzymes are mentioned in Table 4.Table 4 Protein and enzymes produced using PMF.

Table 4Protein/Enzyme	Plant	Functions	Application	Reference	
Aprotinin	N. benthamiana	Serine protease inhibitor	Therapeutic	[304]	
Artemisinin	Artemisia	Malaria	Therapeutic	[167]	
Avidin	Maize	–	Diagnostics	[8]	
Basic fibroblast growth factor	Tobacco	–	Clinical	[305]	
Dentin matrix protein 1	Tobacco	Osteogenic differentiation	–	[306]	
DesB30	Arabidopsis	Insulin	Pharmaceutical Protein	[164]	
Factor H	P. patens	–	Therapeutic	[307]	
Glucocerebrosidase	Carrot cell suspension	Gaucher's disease	Therapeutic enzyme	[308,309]	
hGH	Pea	–	Therapeutic	[310]	
hGH	Tobacco	–	Therapeutic	[311]	
hOAT	Lettuce	Antibodies	Therapeutic	[312]	
Hirudin	Canola	Thrombin inhibitor	Therapeutic	[293]	
Human aprotinin	Maize	Trypsin inhibitor	–	[313]	
Human enkephalins	Arabidopsis	Antihyperanalgesic by opiate activity	Therapeutic	[314]	
Human erythropoietin	Tobacco	Anaemia	Therapeutic	[314]	
Human granulocyte-macrophage colony-stimulating factor	Tobacco	Neutropenia	–	[126]	
Human hemoglobin	Tobacco	Blood substitute	Pharmaceutical Protein	[315]	
Human hirudin	Rapeseed	Thrombin inhibitor	Therapeutic	[315]	
Human homotrimeric collagen	Tobacco	Collagen	Pharmaceutical Protein	[316]	
Human interferon	Rice, turnip, Tobacco	Hepatitis C and B treatment	Therapeutic	[314,315]	
Human lactoferrin	Potato	Antimicrobial	Therapeutic	[58]	
Human lysozyme protein	Rice endosperm	GI infections in infants	Nutraceuticals	[317]	
Human protein C	Tobacco	Anticoagulant	Pharmaceutical Protein	[315]	
Human serum albumin	Tobacco	–	Pharmaceutical Protein	[318]	
Human somatotropin, chloroplast/Nuc	Tobacco	Growth hormone	Pharmaceutical Protein	[319]	
Human α-1-antitrypsin	Rice, Maize	Cystic fibrosis, liver disease, and Rice Human -1-antitrypsin	–	[293,313]	
Insulin	Arabidopsis	–	Pharmaceutical Protein	[320]	
Insulin	Tobacco	–	Diabetes treatment	[321]	
Interleukin-2	Tobacco	–	Therapeutic	[322]	
Lactoferrin	Rice, Tomato	–	Multifunctional	[323]	
Lumbrokinase	Sunflower	anti-thrombosis protein	Therapeutic	[324]	
Lysozyme	Rice	–	Numerous	[325]	
Osteopontin	N. benthamiana	Dental bone regeneration	Therapeutic	[306]	
Polyhydroxybuterate	Tobacco	–	Plastic production	[326]	
β- Galactosidase	Tobacco, maize	Thermostable cellulolytic enzymes	Industrial	[327]	
Zmapp™	N. benthamiana	Ebola Zaire virus	Therapeutic	[11]	
VEN BETA	Rice	Gastroenteritis	–	
Optibumin	Rice	Loss of albumin	–	
Elelyso	Carrot	Gaucher's disease	Therapeutic	[328]	
VEN 100	Rice	Lactoferrin	–	
Canine interferon alpha	Strawberry	–	–	
Gastric lipase	Maize	Cystic fibrosis	Therapeutic		
α-interferon	Rice, Turnip	Anticancer	Pharmaceutical Protein	[293]	
α-Galactosidase	Tobacco	Fabry disease	Therapeutic	Adopted and modified [329]	
α-interferon	Duckweed	Hepatitis B and C	Therapeutic	
Fibrinolytic drug	Duckweed	Blood clot	Therapeutic	
Insulin	Safflower	Diabetes	Therapeutic	
Apolipoprotein	Safflower	Cardiovascular	Therapeutic	

4.4 Secondary metabolites produced by plants' expression system

Tobacco has several distinct benefits across other plant species when it involves protein production with clinical execution. Scientists think that tobacco plays a similar function in research on recombinant proteins as the white mice have in mammalian studies during the past decade. A rare lysosomal storage disorder called Gaucher disease (GD) is caused by mutations in the genes that code for the enzyme -GCase. Several nations have authorized the use of plant-derived taliglucerase alfa as an enzyme substitution therapeutics for the treatment of GD [159]. Trigonella foenum-graceum has been found to contain diosgenin, a triterpene with several pharmacological uses. Using the hairy roots (HR) culture platform and the pBI121 expression plasmid, the rate-limiting enzyme in the diosgenin biosynthesis, Δ24-reductase, has been overexpressed. Compared to non-transgenic HR, the Δ24-reductase expression level was substantially 8.15 times higher in transgenic HR. Additionally, it was increased 25 times when compared to the diosgenin quantity in the "Hamedan" Leaf. The diosgenin aggregation in the transgenic HR was increased three times over the non-transgenic HR [168]. Columbamine O-methyltransferase (CoOMT) is a key catalytic enzyme involved in the biosynthesis of the tetrahydropalmatine path in the alkaloid biosynthetic pathways of Stephania and Rannunculaceae. Its transcription rates were greater in three transgenic tobacco lines from the T0 generation (T0-7, 9, and 20) than in the WT tobacco plants. When compared to tobacco WT, the CoOMT transgenic lines had an estimated 1.09–1.83-fold higher total alkaloid load [169]. Fu et al. [170] investigated the function of EpOPR1 in the synthesis of these secondary metabolites further using a transgenic HR system. This study revealed that although the chemical characteristics of EpOPR1 overexpressing HR and empty vector HR are comparable, overexpressing EpOPR1 line significantly elevated the production of acetyl-shikonin by roughly two-fold. The current studies on the use of plant bioreactors to create compounds with a variety of biological functions, such as anti-Alzheimer, antibacterial, antihemolytic, anti-inflammatory, anti-inflammatory, anti-tumor, and insecticide properties [171]. Some of the plant-derived secondary metabolites are mentioned in Table 5.Table 5 Secondary metabolites production in PMF system.

Table 5Secondary Metabolites	Plants	Culture type	Reference	
Acetylshikonin	Echium plantagineum	Hairy root	[170]	
Alkaloids	N. tabacum	Transgenic	[169]	
Diosgenin	Trigonella foenum-graceum	Hairy root	[168]	
Artemisinin	Aconitum heterophyllum	Hairy root	[330]	
baicalin, baicalein, wogonin	Scutellaria baicalensis	Hairy root	
Chlorogenic acid	Platycodon grandiflorum	Hairy root	
Diosgenin, Prolin	Helicteres isora	Hairy root	
Dopamine	Portulaca oleracea	Hairy root	
Emodin, Physcion	Polygonum multiflorum	Hairy root	
Glycyrrhizin	Abrus precatoroius	Hairy root	
Hydroxycinnamate	Cichorium intybus	Hairy root	
Mitragynine, Ursolic Acid	Mitragyna speciosa	Hairy root	
Podophyllotoxin	Liunm mucronatum	Hairy root	
Salidroside	Rhodiola crenulata	Hairy root	
Silymarin	Silybum marianum	Hairy root	

5 The rise of PMF products in today's market

Many r-proteins derived from plants have been produced, with a few of them bringing it to market. The shortened form of γ-zein, marketed under the brand name Zera® by Era Biotech in Spain, depends on fusing its N-terminal region with other proteins to trigger the production of protein bodies. These protein bodies based on γ-zein can be used to encapsulate r-proteins and exhibit immunostimulatory properties, which could be advantageous for the delivery of vaccines [172]. The higher expression level of recombinant β-Glucuronidases and egg white avidin derived from transgenic maize and commercially marked by Merck Merck via its subsidiary MilliporeSigma. The physiological characterization of maize-derived avidin exhibited an identical N-terminal sequence of egg white and antigenic similarities [173]. Taliglucerase alfa is the only biopharmaceutical product produced in plant cell suspension cultures that has been approved for commercialization thus far after the completion of phase I–III human trials and this recombinant human glucocerebrosidase currently marketed by the Israeli company Protalix Biotherapeutics [174]. Elelyso, a product of taliglucerase alfa, was introduced into the market in May 2012 after receiving FDA approval for injection use as an enzyme substitute for adult patients suffering from Gaucher's disease. Lectins, GF, and cytokines transiently produced in N. benthamiana for research reagents by iBio, Inc. COVIFENZ (SARS-CoV-2 virus-like particles) produced transiently in N. benthamiana for human vaccines by Medicago, Inc [175]. Pembrolizumab (“Keytruda” marketed by Merck, USA) and nivolumab (“Opdivo” marketed by Bristol-Myers Squibb, USA) are mAbs that are utilized in cancer immunotherapy to improve the immune response against cancer cells by targeting the T cell programmed cell death protein 1 (PD-1) receptor. These both have received approval for the treatment of different cancers and have demonstrated a notable improvement in survival rates as well as a reduced progression of the disease in patients with conditions like lung cancer, melanoma, and Hodgkin lymphoma [176]. These examples showcase the diverse range of PMF products that can be successfully developed using plant-based biopharmaceutical engineering systems.

6 Manufacturers in alternative food proteins development

PMF is an alternative method of producing protein that allows animal proteins to be produced in plants by combining precision fermentation techniques with plant agriculture. The list of publicly traded alternative protein firms is small but growing, with Moolec Science becoming the first plant molecular farming company to go public in early 2023. The newest product "Piggy Sooy" from Moolec produced a notably substantial amount of pork protein, marking an exceptional achievement in the company's Meat Replacements Program for the Soybean platform. Up to 26.6 % of the total soluble protein in soy seeds, the animal protein expressed itself at a high level, four times greater than the company had predicted. Although Moolec's soybeans are the same shade of pink as the pig, the outcome is readily apparent [177]. Recombinant lactoglobulin/casein in soybean is produced by Nobell Foods. They exhibit the fusion expression of lactoglobulin and casein, which can subsequently be cleaved upon isolation. These methods use plant expression systems to produce whey and casein, two important dairy protein constituents, at the same time [178]. Miruku also developing PMF systems for producing dairy proteins [179]. Growth factors for cultured meat medium and pharmaceuticals are produced by Tiamet Sciences and Bright Biotech currently working on the development of Transforming Growth Factor β3 and Fibroblast Growth Factor 2. PoLoPo is going to take the place of animal-based proteins in plants. With the help of their innovative SuperAA platform, each potato may become a mini bio-factory and produce animal-based proteins. Veloz Bio is a biotechnology company also developing animal proteins (e.g. egg proteins) in plants. The goal of BioBetter is to provide high-quality, cost effective recombinant bovine growth factors. BioBov FGF2, BioBov Insulin, and BioBov Transferrin are successfully produced and currently working to develop three more GF: BioBov TGFb1, BioBov IGF-1, and BioBov Activin A. An animal protein called chymosin, which is present in the intestines of goats and calves and may also be made by fermentation, is already produced by the Bioceres spinout firm using GM safflower [180]. Current manufactures and developers of PMF products are presented in Table 6.Table 6 Commercial land scape of PMF products.

Table 6Company	Country	Products	Website	
Vytrus Biotech	Spain	Cosmetic ingredient	https://www.vytrus.com/	
Samabriva	France	r-proteins	https://samabriva.com/	
Protalix BioTherapeutics	Israel	ELELYSO®, r-proteins	https://protalix.com/	
PlantForm	Canada	Keytruda®, ranibizumab drug, PhD9 antibody, rBuChE, Hemopexin, Lucentis®	https://www.plantformcorp.com/	
Plant Advanced Technologies	France	r-proteins, cosmetic	https://www.plantadvanced.com/	
Planet Biotechnology	USA	Plantibodies (CMG2-Fc, DPP4-Fc)	https://www.planetbiotechnology.com/	
Phyton Biotech	USA	Paclitaxel, Docetaxel	https://phytonbiotech.com/	
ORF Genetics	Iceland	MESOkine, ISOkine, DERMOkine	https://www.orfgenetics.com/	
Nomad Bioscience	Germany	Vaccines	https://www.nomadbioscience.com/	
Medicago	Canada	Seasonal flu vaccine	https://www.medicagogroup.com/	
Mapp Biopharmaceutical	USA	mAbs	https://mappbio.com/	
Leaf expression systems	UK	Antibodies, VLPs, Enzymes	https://www.leafexpressionsystems.com/	
KBio	California	mAbs, Vaccines		
Icon Genetics	Germany	Vaccines	https://www.icongenetics.com/	
iBio Inc	USA	mAbs, Vaccines	https://ibioinc.com/	
ZIP Solutions	Spain	Vaccines	https://zipsolutions.cat/	
Diamante SRL	Italy	Vaccines	https://www.diamante.tech/	
CollPlant	Israel	Collagen	https://collplant.com/	
AntoXa	Canada	PhD9, rBuChE, Hemopexin	https://antoxacorp.com/	
Agrenvec	Spain	Diagnostic antibodies and growth factors	https://www.agrenvec.es/	

7 Bio-safety concerns of PMF products

Several problems were noticed when thinking about edible vaccinations. It was unclear which classification the edible vaccines should fall under or which part of it-whether the antigen itself, genetically modified produce, or transgenic seeds-needs to be licensed. To make sure they don't get into the food supply, the regulatory organizations give it an extensive review [181]. There are specific problems with edible vaccines right now, and their future relies on several factors. The development of the edible vaccine is heavily reliant on public acceptance. The advantages and applications of edible vaccines should be known by society [182]. An edible vaccine offers a cost-effective, safe, and better disease prevention compared to conventionally developed vaccines. The use of MF techniques poses various biosafety issues, which include the spread of transgenes in the environment, the accumulation of r-proteins in the ecosystem, the contamination of food and feed chains with transgenes and related products, and the safety and quality of the products. Plant molecular farming brings up some new difficulties with factors like transgene amplification, diffusion, and accumulation of harmful r-proteins that might lead to the need for biosafety concerns about contamination of the environment [183]. Several methods are employed to minimize the potential risks associated with PMF. Physical containment is one such strategy, which entails growing GM plants inside of physical structures. Another strategy is called spatial confinement, which combines several approaches to minimize the spread of transgenes and their products. However, the large-scale manufacturing of biotechnology products sparks a debate on the topic of economic effect, waste management, biosafety, and bioethical concerns [184]. All molecular farming-related genetically modified plants, like all other GM plants, must undergo a thorough risk assessment before being allowed to be used in the field. The nature of the recombinant genes employed in PMF brings additional challenges and issues that might necessitate the addition of specialized biosafety considerations to the framework for evaluating the risk of GM plants used for food, feed, or processing. PMF unveils several challenges, including those pertaining to manufacturing procedures, biosafety, and product safety. Among the major obstacles are illustrated in Fig. 2.Fig. 2 Challenges of PMF in plants include various aspects related to safety and production processes.

Fig. 2

PMF products to go through extensive evaluations of potential health and environmental risks prior to field testing, commercialization, and distribution. The evaluation makes sure they don't endanger the environment or public health. In Asia, the regulatory procedure for products derived from molecular farming which uses genetically modified organisms to create medications or other useful compounds can differ greatly from nation to nation. Regulatory agencies in each nation or area are usually in responsible for approving these kinds of products. US: The U.S. Food and Drug Administration (FDA) oversees and grants approval for plant-derived recombinant pharmaceuticals through its Centre for Biologics Evaluation and Research (CBER) and Centre for Drug Evaluation and Research (CDER). The US Department of Agriculture (USDA) controls the introduction and cultivation of GM plants into the environment through its Animal and Plant Health Inspection Service (APHIS) [185,186]; European Union: The European Medicines Agency (EMA) assesses and approves recombinant medicines derived from plants for use within the EU. The EMA's Committee for Medicinal Products for Human Use (CHMP) oversees the scientific evaluation process. The European Food Safety Authority (EFSA) assesses the safety of GMOs and goods made from them within the EU, including plant-derived medications [187,188]. India: GMOs and their products, including those used in MF, must be assessed, and approved by the Genetic Engineering Appraisal Committee (GEAC), which is housed under the Ministry of Environment, Forest and Climate Change and Department of Biotechnology (DBT), Review Committee on Genetic Manipulation (RCGM) under the Ministry of Science and Technology [189]. China: The Ministry of Agriculture and Rural Affairs (MARA) [190]; Japan: The Ministry of Agriculture, Forestry, and Fisheries (MAFF) and the Ministry of Health, Labour, and Welfare (MHLW), Ministry of Economy, Trade and Industry (METI), Ministry of Education, Culture, Sports, Science and Technology (MEXT), Ministry of Finance (MOF), Ministry of the Environment (MOE) [191]; South Korea: the Ministry of Food and Drug Safety (MFDS) and five central administrative agencies [192]; Taiwan: The Council of Agriculture (COA) is responsible for regulating GMOs and associated products [193]. Other Asian countries such Thailand, Malaysia, Indonesia, and others have their own regulatory bodies for assessing GMOs/GMO products [194,195].

8 Perspective and conclusion

Production of r-protein from plants has plenty of benefits, but industrial adoption is hampered by the fact that mammalian and other cell cultures have long existed and are very well understood in an industrial setting, which makes it difficult for plant-based productions to attain market interest. To tilt the scales in favor of sustainable PMF goods, it may be necessary to utilize the extra potential of PMF systems. Regarding the launch of protein products on a large-scale market, PMF is currently a niche platform. One of the biggest restrictions may be the huge cell size of plants and the consequently reduced number of protein synthesis factories per unit volume compared to mammalian and microbial systems. However, the PMF-produced proteins have huge distinct advantages, such as advanced glycan alteration mechanism, the ability to produce allergens and diagnostic proteins without the use of animal components or endotoxins (which is crucial for the creation of pharmaceuticals for some religious communities, vegans, and individuals with animal allergies), and the ability to produce therapeutics and mucosal vaccines at a reasonable cost because oral and topical administration does not require the use of high-cost downstream techniques. Future research must demonstrate that the above-mentioned advantages can be put into practice and scaled into an actual manufacturing process with associated by-products, which has not yet been done to create side streams that do not contain proteins. For further gains in process income, it will be critical to find innovative, mid-to-high-value by-products that can be produced economically from the leftover biomass. In contrast to traditional expression methods to produce non-pharmaceutical and pharmaceutical goods, plants have both techno-economic benefits. The many PMF systems, including chloroplast, nuclear and transient expression, and viral transfection systems, each have remarkable qualities that make it possible for them to develop a variety of diverse product “targets” while experiencing fewer production restrictions quickly and efficiently. The PMF platform has recently overcome several scientific and technological difficulties. Nevertheless, an important barrier to the plant system's broad adoption is the regulatory complexity connected to the manufacturing of therapeutic proteins. The non-pharmaceutical protein commercialization is simple and quicker owing to minimal regulatory problems because of the economical and higher scalability of PMF production techniques. Therefore, the global regulatory environment and constraints placed on items made from plants will have a notable impact on whether the technology is accepted by all people. A promising future for PMF biologics is suggested by the demand for r-proteins that are valuable for industry or pharmaceuticals, as well as by the system's established manufacturing capabilities and economic viability.

9 Search strategy

A systematic review was performed to explore the recombinant products produced in plant platforms. All pertinent research focusing on development strategies for PMF and discussing the PMF products such as mABs, vaccines, proteins, enzymes, pharmaceutical and nonpharmaceutical molecules and its developments. Select respected academic resources like PubMed, Scopus, Web of Science, Limaps, Consensus, and Google Scholar, as well as specialist databases related to the topic, such as Plant Cell Reports for plant molecular farming. Apply pertinent filters, such as publication date, language, and document type, to refine the results of your methodical searches in these databases by utilizing the defined keywords and Boolean operators. A range of keywords combinations were used in search terms, plant molecular farming, plant bioreactors, plant expression system, plantibodies, vaccine produced in plants, biopharmaceuticals, recombinant proteins and enzymes, transient expression system, PMF products. To find other studies, the reference lists of pertinent papers and reviews were also manually searched. Abstracts from conferences, patents, and organisational reports are examples of grey literature that should be included. The therapeutic roles of PMF products were also examined in observational studies, clinical trials, and experimental investigations. First, the relevance of the search results was screened, and then the eligibility of the complete text was evaluated. Selected studies' data were carefully extracted and thematically arranged.

Funding

Not applicable.

CRediT authorship contribution statement

Jothi Kanmani Bharathi: Writing – original draft, Methodology. Preethika Suresh: Methodology, Data curation. Muthu Arjuna Samy Prakash: Writing – review & editing, Validation, Supervision. Sowbiya Muneer: Writing – review & editing, Validation, Supervision, Funding acquisition.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgements

The authors would also like extend their acknowledgment to 10.13039/501100004728 Vellore Institute of Technology , Vellore, India for article publishing charges.
==== Refs
References

1 Fischer R. Buyel J.F. Molecular farming – the slope of enlightenment Biotechnol. Adv. 40 2020 107519 10.1016/j.biotechadv.2020.107519
2 Singh A. Rajput V. Singh A.K. Sengar R.S. Singh R.K. Minkina T. Chapter 23 - transformation techniques and their role in crop improvements Singh P. Borthakur A. Singh A.A. Kumar A. K.K.B.T.-P.I. in G.M.C. Singh A Global Scenario of GM Crops 2021 Academic Press 515 542 10.1016/B978-0-12-820780-2.00023-6
3 Allied Market Research Plant-based biologics market size, share, competitive landscape and trend analysis report by product type (Leaf-based, seed-based, fruit-based, others), by source (carrot, tobacco, rice, duckweed, others), by target disease (gaucher disease, Fabry disease https://www.alliedmarketresearch.com/plant-based-biologics-market-A74549#:∼:text 2023
4 Daniell H. Streatfield S.J. Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants Trends Plant Sci. 6 2001 219 226 11335175
5 Buyel J.F. Stöger E. Bortesi L. Targeted genome editing of plants and plant cells for biomanufacturing Transgenic Res. 30 2021 401 426 33646510
6 Sharma A.K. Sharma M.K. Plants as bioreactors: recent developments and emerging opportunities Biotechnol. Adv. 27 2009 811 832 19576278
7 Leite M.L. Sampaio K.B. Costa F.F. Franco O.L. Dias S.C. Cunha N.B. Molecular farming of antimicrobial peptides: available platforms and strategies for improving protein biosynthesis using modified virus vectors, An. Acad Bras. Cienc. 91 2018
8 Hood E.E. Witcher D.R. Maddock S. Meyer T. Baszczynski C. Bailey M. Flynn P. Register J. Marshall L. Bond D. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification Mol. Breed. 3 1997 291 306
9 Obembe O.O. Popoola J.O. Leelavathi S. V Reddy S. Advances in plant molecular farming Biotechnol. Adv. 29 2011 210 222 21115109
10 Shanmugaraj B. Bulaon C.J.I. Phoolcharoen W. Plant molecular farming: a viable platform for recombinant biopharmaceutical production Plants 9 2020 842 32635427
11 Clark M. Maselko M. Transgene biocontainment strategies for molecular farming Front. Plant Sci. 11 2020 210 32194598
12 He Y. Ning T. Xie T. Qiu Q. Zhang L. Sun Y. Jiang D. Fu K. Yin F. Zhang W. Large-scale production of functional human serum albumin from transgenic rice seeds Proc. Natl. Acad. Sci. 108 2011 19078 19083 22042856
13 Fischer R. Emans N. Molecular farming of pharmaceutical proteins Transgenic Res. 9 2000 279 299 10.1023/A:1008975123362 11131007
14 Kumari S. Tennakoon I. Molecular farming: implication for future pharmaceutical products Sri Lankan J. Heal. Sci. 1 2022
15 SP S.M.S. Siridewa K. Molecular pharming: a new approach for a healthy future by a vast development in the pharmaceutical industry Curr. Trends Biotechnol. Pharm. 15 2021 315 324
16 Gleba Y. Klimyuk V. Marillonnet S. Magnifection—a new platform for expressing recombinant vaccines in plants Vaccine 23 2005 2042 2048 15755568
17 Schillberg S. Raven N. Fischer R. Twyman R.M. Schiermeyer A. Contained molecular farming using plant cell and tissue cultures Appl. Bioeng. Innov. Futur. Dir. 2017 259 281
18 Howard J.A. Hood E. Bioindustrial and biopharmaceutical products produced in plants Adv. Agron. 85 2005 91 124
19 Rajeevkumar S. Anunanthini P. Sathishkumar R. Epigenetic silencing in transgenic plants Front. Plant Sci. 6 2015 693 10.3389/fpls.2015.00693 26442010
20 Miki D. Zhang W. Zeng W. Feng Z. Zhu J.-K. CRISPR/Cas9-mediated gene targeting in Arabidopsis using sequential transformation Nat. Commun. 9 2018 1967 10.1038/s41467-018-04416-0 29773790
21 Rönspies M. Schindele P. Wetzel R. Puchta H. CRISPR–Cas9-mediated chromosome engineering in Arabidopsis thaliana Nat. Protoc. 17 2022 1332 1358 10.1038/s41596-022-00686-7 35388178
22 Svitashev S. Young J.K. Schwartz C. Gao H. Falco S.C. Cigan A.M. Targeted mutagenesis, precise gene editing, and site-specific gene insertion in maize using Cas9 and guide RNA Plant Physiol. 169 2015 931 945 26269544
23 Watanabe K. Breier U. Hensel G. Kumlehn J. Schubert I. Reiss B. Stable gene replacement in barley by targeted double-strand break induction J. Exp. Bot. 67 2016 1433 1445 26712824
24 Li J. Meng X. Zong Y. Chen K. Zhang H. Liu J. Li J. Gao C. Gene replacements and insertions in rice by intron targeting using CRISPR–Cas9 Nat. Plants 2 2016 16139 10.1038/nplants.2016.139
25 Bonawitz N.D. Ainley W.M. Itaya A. Chennareddy S.R. Cicak T. Effinger K. Jiang K. Mall T.K. Marri P.R. Samuel J.P. Zinc finger nuclease‐mediated targeting of multiple transgenes to an endogenous soybean genomic locus via non‐homologous end joining Plant Biotechnol. J. 17 2019 750 761 10.1111/pbi.13012 30220095
26 Daniell H. Jin S. Zhu X. Gitzendanner M.A. Soltis D.E. Soltis P.S. Green giant—a tiny chloroplast genome with mighty power to produce high‐value proteins: history and phylogeny Plant Biotechnol. J. 19 2021 430 447 33484606
27 Sahoo S. Das S.S. Rakshit R. Codon usage pattern and predicted gene expression in Arabidopsis thaliana Gene 721 2019 100012 10.1016/j.gene.2019.100012
28 Peyret H. Brown J.K.M. Lomonossoff G.P. Improving plant transient expression through the rational design of synthetic 5′ and 3′ untranslated regions Plant Methods 15 2019 108 10.1186/s13007-019-0494-9 31548848
29 Singh A.A. Pillay P. Tsekoa T.L. Engineering approaches in plant molecular farming for global health Vaccines 9 2021 1270 34835201
30 Wang X. Karki U. Abeygunaratne H. UnnoldCofre C. Xu J. Plant cell-secreted stem cell factor stimulates expansion and differentiation of hematopoietic stem cells Process Biochem 100 2021 39 48 10.1016/j.procbio.2020.09.029 33071562
31 Jiang M.-C. Hu C.-C. Lin N.-S. Hsu Y.-H. Production of human IFNγ protein in Nicotiana benthamiana plant through an enhanced expression system based on bamboo mosaic virus Viruses 11 2019 10.3390/v11060509
32 Rybicki E.P. Plant‐made vaccines for humans and animals Plant Biotechnol. J. 8 2010 620 637 20233333
33 Kawakatsu T. Takaiwa F. Reduction of 13 kD prolamins increases recombinant protein yield and recovery rate in rice endosperm Plant Signal. Behav. 7 2012 1402 1403 10.4161/psb.21924 22960759
34 Yuki Y. Mejima M. Kurokawa S. Hiroiwa T. Kong I.G. Kuroda M. Takahashi Y. Nochi T. Tokuhara D. Kohda T. Kozaki S. Kiyono H. RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine Vaccine 30 2012 4160 4166 10.1016/j.vaccine.2012.04.064 22554467
35 Shigemitsu T. Ozaki S. Saito Y. Kuroda M. Morita S. Satoh S. Masumura T. Production of human growth hormone in transgenic rice seeds: co-introduction of RNA interference cassette for suppressing the gene expression of endogenous storage proteins Plant Cell Rep. 31 2012 539 549 10.1007/s00299-011-1191-y 22108719
36 Lyzenga W.J. Harrington M. Bekkaoui D. Wigness M. Hegedus D.D. Rozwadowski K.L. CRISPR/Cas9 editing of three CRUCIFERIN C homoeologues alters the seed protein profile in Camelina sativa BMC Plant Biol. 19 2019 292 10.1186/s12870-019-1873-0 31272394
37 Li A. Jia S. Yobi A. Ge Z. Sato S.J. Zhang C. Angelovici R. Clemente T.E. Holding D.R. Editing of an alpha-kafirin gene family increases, digestibility and protein quality in sorghum Plant Physiol 177 2018 1425 1438 10.1104/pp.18.00200 29925584
38 Jeong J. Jeon E. Song Y.J. Hwang M.K. Gwak Y. Kim J.-Y. Impact of CRISPR/Cas9-induced mutations in nicotine biosynthesis core genes A622 and BBL on tobacco: reduction in nicotine content and developmental abnormalities Curr. Plant Biol. 38 2024 100343 10.1016/j.cpb.2024.100343
39 Hayashi S. Watanabe M. Kobayashi M. Tohge T. Hashimoto T. Shoji T. Genetic manipulation of transcriptional regulators alters nicotine biosynthesis in tobacco Plant Cell Physiol. 61 2020 1041 1053 32191315
40 Yang D.Q. Zeng J. Sun X.Y. Yue X. Hu C.X. Jiang P. Liu R.D. Cui J. Wang Z.Q. Trichinella spiralis: RNAi-Mediated Silencing of Serine Protease Results in Reduction of Intrusion, Development and Fecundity 2020
41 Pillay P. Kibido T. du Plessis M. van der Vyver C. Beyene G. Vorster B.J. Kunert K.J. Schlüter U. Use of transgenic oryzacystatin-I-expressing plants enhances recombinant protein production Appl. Biochem. Biotechnol. 168 2012 1608 1620 10.1007/s12010-012-9882-6 22965305
42 Strasser R. Altmann F. Steinkellner H. Controlled glycosylation of plant-produced recombinant proteins Curr. Opin. Biotechnol. 30 2014 95 100 10.1016/j.copbio.2014.06.008 25000187
43 Liu H. Timko M.P. Improving protein quantity and quality - the next level of plant molecular farming Int. J. Mol. Sci. 23 2022 1326 35163249
44 Castilho A. Steinkellner H. Glyco‐engineering in plants to produce human‐like N‐glycan structures Biotechnol. J. 7 2012 1088 1098 22890723
45 Gomord V. Fitchette A. Menu‐Bouaouiche L. Saint‐Jore‐Dupas C. Plasson C. Michaud D. Faye L. Plant‐specific glycosylation patterns in the context of therapeutic protein production Plant Biotechnol. J. 8 2010 564 587 20233335
46 Margolin E. Crispin M. Meyers A. Chapman R. Rybicki E.P. A roadmap for the molecular farming of viral glycoprotein vaccines: engineering glycosylation and glycosylation-directed folding Front. Plant Sci. 11 2020 609207
47 Göritzer K. Grandits M. Grünwald-Gruber C. Figl R. Mercx S. Navarre C. Ma J.K.C. Teh A.Y.H. Engineering the N-glycosylation pathway of Nicotiana tabacum for molecular pharming using CRISPR/Cas9 Front. Plant Sci. 13 2022 1003065
48 Santos R.B. Abranches R. Fischer R. Sack M. Holland T. Putting the spotlight back on plant suspension cultures Front. Plant Sci. 7 2016 182204
49 Wilson S.A. Roberts S.C. Recent advances towards development and commercialization of plant cell culture processes for the synthesis of biomolecules Plant Biotechnol. J. 10 2012 249 268 22059985
50 Holland T. Buyel J.F. Bioreactor-based production of glycoproteins in plant cell suspension cultures Picanço-Castro V. Swiech K. Recomb. Glycoprotein Prod. Methods Protoc. 2018 Springer New York, New York, NY 129 146 10.1007/978-1-4939-7312-5_11
51 Michoux F. Ahmad N. Hennig A. Nixon P.J. Warzecha H. Production of leafy biomass using temporary immersion bioreactors: an alternative platform to express proteins in transplastomic plants with drastic phenotypes Planta 237 2013 903 908 10.1007/s00425-012-1829-1 23262582
52 Michoux F. Ahmad N. McCarthy J. Nixon P.J. Contained and high‐level production of recombinant protein in plant chloroplasts using a temporary immersion bioreactor Plant Biotechnol. J. 9 2011 575 584 21105992
53 Kang T.-J. Lee W.-S. Choi E.-G. Kim J.-W. Kim B.-G. Yang M.-S. Mass production of somatic embryos expressing Escherichia coli heat-labile enterotoxin B subunit in Siberian ginseng J. Biotechnol. 121 2006 124 133 10.1016/j.jbiotec.2005.07.020 16174540
54 Moon K.-B. Park J.-S. Park Y.-I. Song I.-J. Lee H.-J. Cho H.S. Jeon J.-H. Kim H.-S. Development of systems for the production of plant-derived biopharmaceuticals Plants 9 2020 10.3390/plants9010030
55 Stoger E. Sack M. Perrin Y. Vaquero C. Torres E. Twyman R.M. Christou P. Fischer R. Practical considerations for pharmaceutical antibody production in different crop systems Mol. Breed. 9 2002 149 158
56 Twyman R.M. Stoger E. Schillberg S. Christou P. Fischer R. Molecular farming in plants: host systems and expression technology TRENDS Biotechnol. 21 2003 570 578 14624867
57 Hood E.E. From green plants to industrial enzymes Enzyme Microb. Technol. 30 2002 279 283
58 Chong D.K.X. Langridge W.H.R. Expression of full-length bioactive antimicrobial human lactoferrin in potato plants Transgenic Res. 9 2000 71 78 10853271
59 Sala F. Rigano M.M. Barbante A. Basso B. Walmsley A.M. Castiglione S. Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives Vaccine 21 2003 803 808 12531364
60 Ziemienowicz A. Agrobacterium-mediated plant transformation: factors, applications and recent advances Biocatal. Agric. Biotechnol. 3 2014 95 102
61 Abiri R. Valdiani A. Maziah M. Shaharuddin N.A. Sahebi M. Yusof Z.N.B. Atabaki N. Talei D. A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming Curr. Issues Mol. Biol. 18 2016 21 42 25944541
62 Alireza T. Nader R.E. Molecular Farming in Plants 2015 IntechOpen
63 Kesik‐Brodacka M. Progress in biopharmaceutical development Biotechnol. Appl. Biochem. 65 2018 306 322 28972297
64 Breedveld F.C. Therapeutic monoclonal antibodies Lancet 355 2000 735 740 10703815
65 Stern A.M. Markel H. The history of vaccines and immunization: familiar patterns, new challenges Health Aff. 24 2005 611 621
66 Waheed M.T. Gottschamel J. Hassan S.W. Lössl A.G. Plant-derived vaccines: an approach for affordable vaccines against cervical cancer Hum. Vaccines Immunother. 8 2012 403 406
67 Guan Z. Guo B. Huo Y. Guan Z. Dai J. Wei Y. Recent advances and safety issues of transgenic plant-derived vaccines Appl. Microbiol. Biotechnol. 97 2013 2817 2840 23447052
68 Piron R. De Koker S. De Paepe A. Goossens J. Grooten J. Nauwynck H. Depicker A. Boosting in planta production of antigens derived from the porcine reproductive and respiratory syndrome virus (PRRSV) and subsequent evaluation of their immunogenicity PLoS One 9 2014 e91386
69 Dirisala V.R. Nair R.R. Srirama K. Reddy P.N. Rao K.R.S.S. Satya Sampath Kumar N. Parvatam G. Recombinant pharmaceutical protein production in plants: unraveling the therapeutic potential of molecular pharming Acta Physiol. Plant. 39 2016 18 10.1007/s11738-016-2315-3
70 Jain A. Saini V. Veer Kohli D. Edible transgenic plant vaccines for different diseases Curr. Pharmaceut. Biotechnol. 14 2013 594 614
71 Spiegel H. Stöger E. Twyman R.M. Buyel J.F. Current status and perspectives of the molecular farming landscape Mol. Pharming Appl. Challenges Emerg. Areas 2018 John Wiley & Sons, Inc. Hoboken, NJ, USA 3 23
72 Tregoning J.S. First human efficacy study of a plant-derived influenza vaccine Lancet 396 2020 1464 1465 33065033
73 Pillet S. Arunachalam P.S. Andreani G. Golden N. Fontenot J. Aye P.P. Röltgen K. Lehmicke G. Gobeil P. Dubé C. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates Cell. Mol. Immunol. 19 2022 222 233 34983950
74 Phoolcharoen W. Bhoo S.H. Lai H. Ma J. Arntzen C.J. Chen Q. Mason H.S. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana Plant Biotechnol. J. 9 2011 807 816 21281425
75 Li Y. Sun M. Liu J. Yang Z. Zhang Z. Shen G. High expression of foot-and-mouth disease virus structural protein VP1 in tobacco chloroplasts Plant Cell Rep. 25 2006 329 333 10.1007/s00299-005-0074-5 16320056
76 Kim M.-Y. Yang M.-S. Kim T.-G. Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants Biotechnol. Bioproc. Eng. 14 2009 725 730 10.1007/s12257-009-3011-6
77 Pollet J. Chen W.-H. Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics Adv. Drug Deliv. Rev. 170 2021 71 82 10.1016/j.addr.2021.01.001 33421475
78 Ceballo Y. Tiel K. López A. Cabrera G. Pérez M. Ramos O. Rosabal Y. Montero C. Menassa R. Depicker A. Hernández A. High accumulation in tobacco seeds of hemagglutinin antigen from avian (H5N1) influenza Transgenic Res. 26 2017 775 789 10.1007/s11248-017-0047-9 28986672
79 Rosales-Mendoza S. Márquez-Escobar V.A. González-Ortega O. Nieto-Gómez R. Arévalo-Villalobos J.I. What does plant-based vaccine technology offer to the fight against COVID-19? Vaccines 8 2020 183 32295153
80 Lobato Gomez M. Huang X. Alvarez D. He W. Baysal C. Zhu C. Armario‐Najera V. Blanco Perera A. Cerda Bennasser P. Saba‐Mayoral A. Contributions of the international plant science community to the fight against human infectious diseases–part 1: epidemic and pandemic diseases Plant Biotechnol. J. 19 2021 1901 1920 34182608
81 Ghorbani A. Zare F. Sazegari S. Afsharifar A. Eskandari M.H. Pormohammad A. Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach New Microbes New Infect 38 2020 100786
82 Li H.Y. Ramalingam S. Chye M.-L. Accumulation of recombinant SARS-CoV spike protein in plant cytosol and chloroplasts indicate potential for development of plant-derived oral vaccines Exp. Biol. Med. 231 2006 1346 1352
83 Charland N. Gobeil P. Pillet S. Boulay I. Séguin A. Makarkov A. Heizer G. Bhutada K. Mahmood A. Trépanier S. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities Npj Vaccines 7 2022 142 36351931
84 Shanmugaraj B. Khorattanakulchai N. Panapitakkul C. Malla A. Im-erbsin R. Inthawong M. Sunyakumthorn P. Hunsawong T. Klungthong C. Reed M.C. Kemthong T. Suttisan N. Malaivijitnond S. Srimangkornkaew P. Klinkhamhom A. Manopwisedjaroen S. Thitithanyanont A. Taychakhoonavudh S. Phoolcharoen W. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: protective efficacy, immunogenicity, safety, and toxicity Vaccine 40 2022 4440 4452 10.1016/j.vaccine.2022.05.087 35697573
85 Khorattanakulchai N. Srisutthisamphan K. Shanmugaraj B. Manopwisedjaroen S. Rattanapisit K. Panapitakkul C. Kemthong T. Suttisan N. Malaivijitnond S. Thitithanyanont A. A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques Front. Plant Sci. 13 2022 901978
86 Margolin E. Verbeek M. de Moor W. Chapman R. Meyers A. Schäfer G. Williamson A.-L. Rybicki E. Investigating constraints along the plant secretory pathway to improve production of a SARS-CoV-2 spike vaccine candidate Front. Plant Sci. 12 2022 798822
87 Margolin E. Schäfer G. Allen J.D. Gers S. Woodward J. Sutherland A.D. Blumenthal M. Meyers A. Shaw M.L. Preiser W. A plant-produced SARS-CoV-2 spike protaein elicits heterologous immunity in hamsters Front. Plant Sci. 14 2023 1146234
88 Chattopadhyay A. Jailani A.A.K. Mandal B. Exigency of plant-based vaccine against COVID-19 emergence as pandemic preparedness Vaccines 11 2023 1347 37631915
89 Loza-Rubio E. Rojas-Anaya E. López J. Olivera-Flores M.T. Gómez-Lim M. Tapia-Pérez G. Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein Vaccine 30 2012 5551 5556 22749836
90 Zhang X. Buehner N.A. Hutson A.M. Estes M.K. Mason H.S. Tomato is a highly effective vehicle for expression and oral immunization Plant Biotechnol. J. 4 2006 419 432 Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid proZhang, X., Buehner, N. A., Hutson, A. M., Estes, M. K., & Mason, H. S. (2006) 17177807
91 Mason H.S. Ball J.M. Shi J.-J. Jiang X. Estes M.K. Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice Proc. Natl. Acad. Sci. 93 1996 5335 5340 8643575
92 Lai H. Chen Q. Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations Plant Cell Rep. 31 2012 573 584 22134876
93 Li T. Sun J.K. Lu Z.H. Liu Q. Transformation of HBsAg (hepatitis B surface antigen) gene into tomato mediated by Agrobacterium tumefaciens, Czech J. Genet. Plant Breed. 47 2011 69 77
94 Wu Y.-Z. Li J.-T. Mou Z.-R. Fei L. Ni B. Geng M. Jia Z.-C. Zhou W. Zou L.-Y. Tang Y. Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA Virology 313 2003 337 342 12954202
95 Richter L.J. Thanavala Y. Arntzen C.J. Mason H.S. Production of hepatitis B surface antigen in transgenic plants for oral immunization Nat. Biotechnol. 18 2000 1167 1171 11062435
96 Tacket C.O. Pasetti M.F. Edelman R. Howard J.A. Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn Vaccine 22 2004 4385 4389 15474732
97 Tacket C.O. Mason H.S. Losonsky G. Estes M.K. Levine M.M. Arntzen C.J. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes J. Infect. Dis. 182 2000 302 305 10882612
98 Yusibov V. Hooper D.C. V Spitsin S. Fleysh N. Kean R.B. Mikheeva T. Deka D. Karasev A. Cox S. Randall J. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine Vaccine 20 2002 3155 3164 12163267
99 Yang M. Sun H. Lai H. Hurtado J. Chen Q. Plant‐produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice Plant Biotechnol. J. 16 2018 572 580 28710796
100 Ward B.J. Makarkov A. Séguin A. Pillet S. Trépanier S. Dhaliwall J. Libman M.D. Vesikari T. Landry N. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials Lancet 396 2020 1491 1503 10.1016/S0140-6736(20)32014-6 33065035
101 Ward B.J. Séguin A. Couillard J. Trépanier S. Landry N. Phase III: randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18–49 years of age Vaccine 39 2021 1528 1533 10.1016/j.vaccine.2021.01.004 33581920
102 Makarkov A.I. Golizeh M. Ruiz-Lancheros E. Gopal A.A. Costas-Cancelas I.N. Chierzi S. Pillet S. Charland N. Landry N. Rouiller I. Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages NPJ Vaccines 4 2019 1 12 30622742
103 Jeshvaghani F.S. Amani J. Kazemi R. Rahjerdi A.K. Jafari M. Abbasi S. Salmanian A.H. Oral immunization with a plant-derived chimeric protein in mice: toward the development of a multipotent edible vaccine against E. coli O157: H7 and ETEC Immunobiology 224 2019 262 269 30579628
104 Chichester J.A. Green B.J. Jones R.M. Shoji Y. Miura K. Long C.A. Lee C.K. Ockenhouse C.F. Morin M.J. Streatfield S.J. Yusibov V. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a Phase 1 dose-escalation study in healthy adults Vaccine 36 2018 5865 5871 10.1016/j.vaccine.2018.08.033 30126674
105 Wang D.M. Zhu J.B. Peng M. Zhou P. Induction of a protective antibody response to FMDV in mice following oral immunization with transgenic Stylosanthes spp. as a feedstuff additive Transgenic Res. 17 2008 1163 1170 18651235
106 Yácono M. Farran I. Becher M.L. Sander V. Sanchez V.R. Martín V. Veramendi J. Clemente M. A chloroplast‐derived T oxoplasma gondii GRA 4 antigen used as an oral vaccine protects against toxoplasmosis in mice Plant Biotechnol. J. 10 2012 1136 1144 23020088
107 Singh A. Srivastava S. Chouksey A. Panwar B.S. Verma P.C. Roy S. Singh P.K. Saxena G. Tuli R. Expression of rabies glycoprotein and ricin toxin B chain (RGP–RTB) fusion protein in tomato hairy roots: a step towards Oral vaccination for rabies Mol. Biotechnol. 57 2015 359 370 25519901
108 Mathew L.G. Herbst-Kralovetz M.M. Mason H.S. Norovirus Narita 104 virus-like particles expressed in Nicotiana benthamiana induce serum and mucosal immune responses BioMed Res. Int. 2014 2014
109 Thuenemann E.C. Meyers A.E. Verwey J. Rybicki E.P. Lomonossoff G.P. A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus‐like particles Plant Biotechnol. J. 11 2013 839 846 23647743
110 Cummings J.F. Guerrero M.L. Moon J.E. Waterman P. Nielsen R.K. Jefferson S. Gross F.L. Hancock K. Katz J.M. Yusibov V. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1) pdm09 virus: a Phase 1 dose-escalation study in healthy adults Vaccine 32 2014 2251 2259 24126211
111 Chichester J.A. Jones R.M. Green B.J. Stow M. Miao F. Moonsammy G. Streatfield S.J. Yusibov V. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adul Viruses 4 2012 3227 3244 23202523
112 Yuki Y. Nojima M. Kashima K. Sugiura K. Maruyama S. Kurokawa S. Yamanoue T. Nakahashi-Ouchida R. Nakajima H. Hiraizumi T. Kohno H. Goto E. Fujihashi K. Kiyono H. Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults Vaccine 40 2022 3372 3379 10.1016/j.vaccine.2022.04.051 35484039
113 MacDonald J. Doshi K. Dussault M. Hall J.C. Holbrook L. Jones G. Kaldis A. Klima C.L. Macdonald P. McAllister T. Bringing plant-based veterinary vaccines to market: managing regulatory and commercial hurdles Biotechnol. Adv. 33 2015 1572 1581 26232717
114 LeBlanc Z. Waterhouse P. Bally J. Plant-based vaccines: the way ahead? Viruses 13 2020 5 33375155
115 Tusé D. Nandi S. McDonald K.A. Buyel J.F. The emergency response capacity of plant-based biopharmaceutical manufacturing-what it is and what it could be Front. Plant Sci. 11 2020 594019
116 Edgue G. Twyman R.M. Beiss V. Fischer R. Sack M. Antibodies from plants for bionanomaterials Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology 9 2017 e1462
117 Xia Z. Structure, classification, and naming of therapeutic monoclonal antibodies, biosimilars monoclon Antibodies A Pract. Guid. to Manuf. Preclin. Clin. Dev. 2016 63 83
118 V Sheshukova E. V Komarova T. Dorokhov Y.L. Plant factories for the production of monoclonal antibodies Biochem. 81 2016 1118 1135 27908237
119 Buyel J.F. Twyman R.M. Fischer R. Very-large-scale production of antibodies in plants: the biologization of manufacturing Biotechnol. Adv. 35 2017 458 465 10.1016/j.biotechadv.2017.03.011 28347720
120 Jhinjer R.K. Verma L. Wani S.H. Gosal S.S. Molecular farming using transgenic approaches Adv. Plant Breed. Strateg. Agron. Abiotic Biot. Stress Trait 2016 Springer 97 145
121 Gul M.Z. Yasin Bhat Y. Kumar A. Rao B.S. Molecular pharming (pharmaceuticals): primary and secondary metabolites in plants Adv. Mol. Plant Breeding, Meet. Challenges Food Secur. Apple 2018 Acad. Press. Inc.(CRC Press. a Taylor Fr. Group, Palm Bay, FL 397 432
122 Moffat A.S. Exploring transgenic plants as a new vaccine source Science 268 1995 658 660 7732373
123 Doran P. Foreign protein production in plant tissue cultures Curr. Opin. Biotechnol. 11 1999 199 204
124 Jain P. Pandey P. Jain D. Dwivedi P. Plantibody: an overview Asian J. Pharm. Life Sci. 1 2011 87 94
125 Oluwayelu D.O. Adebiyi A.I. Plantibodies in human and animal health: a review Afr. Health Sci. 16 2016 640 645 27605982
126 Choi Y.-S. Moon J.-H. Kim T.-G. Lee J.-Y. Potent in vitro and in vivo activity of plantibody specific for Porphyromonas gingivalis FimA Clin. Vaccine Immunol. 23 2016 346 352 26865596
127 Vamvaka E. Twyman R.M. Murad A.M. Melnik S. Teh A.Y. Arcalis E. Altmann F. Stoger E. Rech E. Ma J.K.C. Rice endosperm produces an underglycosylated and potent form of the HIV‐neutralizing monoclonal antibody 2G12 Plant Biotechnol. J. 14 2016 97 108 25845722
128 Ma J.K. Drossard J. Lewis D. Altmann F. Boyle J. Christou P. Cole T. Dale P. van Dolleweerd C.J. Isitt V. Regulatory approval and a first‐in‐human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants Plant Biotechnol. J. 13 2015 1106 1120 26147010
129 Seber Kasinger L.E. Dent M.W. Mahajan G. Hamorsky K.T. Matoba N. A novel anti‐HIV‐1 bispecific bNAb‐Lectin fusion protein engineered in a plant‐based transient expression system Plant Biotechnol. J. 17 2019 1646 1656 30729651
130 Rosenberg Y. Sack M. Montefiori D. Labranche C. Lewis M. Urban L. Mao L. Fischer R. Jiang X. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques PLoS One 10 2015 e0120451
131 Vamvaka E. Farré G. Molinos-Albert L.M. Evans A. Canela-Xandri A. Twyman R.M. Carrillo J. Ordóñez R.A. Shattock R.J. O'Keefe B.R. Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm Proc. Natl. Acad. Sci. 115 2018 E7854 E7862 30061386
132 Hensel G. Floss D.M. Arcalis E. Sack M. Melnik S. Altmann F. Rutten T. Kumlehn J. Stoger E. Conrad U. Transgenic production of an anti HIV antibody in the barley endosperm PLoS One 10 2015 e0140476 10.1371/journal.pone.0140476
133 Vasilev N. Smales C.M. Schillberg S. Fischer R. Schiermeyer A. Developments in the production of mucosal antibodies in plants Biotechnol. Adv. 34 2016 77 87 26626615
134 Nakanishi K. Takase T. Ohira Y. Ida R. Mogi N. Kikuchi Y. Matsuda M. Kurohane K. Akimoto Y. Hayakawa J. Prevention of Shiga toxin 1-caused colon injury by plant-derived recombinant IgA Sci. Rep. 12 2022 1 13 34992227
135 Loos A. Van Droogenbroeck B. Hillmer S. Grass J. Kunert R. Cao J. Robinson D.G. Depicker A. Steinkellner H. Production of monoclonal antibodies with a controlled N‐glycosylation pattern in seeds of Arabidopsis thaliana Plant Biotechnol. J. 9 2011 179 192 20561245
136 Zischewski J. Sack M. Fischer R. Overcoming low yields of plant‐made antibodies by a protein engineering approach Biotechnol. J. 11 2016 107 116 26632507
137 Olinger G.G. Jr. Pettitt J. Kim D. Working C. Bohorov O. Bratcher B. Hiatt E. Hume S.D. Johnson A.K. Morton J. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Proc. Natl. Acad. Sci. 109 2012 18030 18035 23071322
138 Rybicki E.P. Plant-based vaccines against viruses Virol. J. 11 2014 1 20 24393133
139 Robert M.-A. Nassoury N. Chahal P.S. Venne M.-H. Racine T. Qiu X. Kobinger G. Kamen A. Gilbert R. Gaillet B. Gene transfer of ZMapp antibodies mediated by recombinant adeno-associated virus protects against Ebola infections Hum. Gene Ther. 29 2017 452 466 10.1089/hum.2017.101
140 Davidson E. Bryan C. Fong R.H. Barnes T. Pfaff J.M. Mabila M. Rucker J.B. Doranz B.J. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies J. Virol. 89 2015 10982 10992 26311869
141 Shanmugaraj B. Rattanapisit K. Manopwisedjaroen S. Thitithanyanont A. Phoolcharoen W. Monoclonal antibodies B38 and H4 produced in Nicotiana benthamiana neutralize SARS-CoV-2 in vitro Front. Plant Sci. 11 2020 589995
142 Juárez P. Presa S. Espí J. Pineda B. Antón M.T. Moreno V. Buesa J. Granell A. Orzaez D. Neutralizing antibodies against rotavirus produced in transgenically labelled purple tomatoes Plant Biotechnol. J. 10 2012 341 352 22070155
143 Zhang J. Zhang H. Sun L. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? MAbs 2022 Taylor & Francis 2031483
144 Paul M. Reljic R. Klein K. Drake P.M.W. Van Dolleweerd C. Pabst M. Windwarder M. Arcalis E. Stoger E. Altmann F. Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV MAbs 2014 Taylor & Francis 1585 1597
145 Lim J.A.C. Patkar A. McDonagh G. Sinclair A. Lucy P. Modeling bioprocess cost BioProcess Int 8 2010 62 70
146 J Paul M. YH Teh A. M Twyman R. KC Ma J. Target product selection-where can Molecular Pharming make the difference? Curr. Pharmaceut. Des. 19 2013 5478 5485
147 Hurtado J. Acharya D. Lai H. Sun H. Kallolimath S. Steinkellner H. Bai F. Chen Q. In vitro and in vivo efficacy of anti‐chikungunya virus monoclonal antibodies produced in wild‐type and glycoengineered Nicotiana benthamiana plants Plant Biotechnol. J. 18 2020 266 273 31207008
148 Politch J.A. Cu-Uvin S. Moench T.R. Tashima K.T. Marathe J.G. Guthrie K.M. Cabral H. Nyhuis T. Brennan M. Zeitlin L. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): a Phase I randomized trial PLoS Med. 18 2021 e1003495
149 Schillberg S. Finnern R. Plant molecular farming for the production of valuable proteins–Critical evaluation of achievements and future challenges J. Plant Physiol. 258 2021 153359
150 Ma S. Wang A. Molecular farming in plants: an overview Mol. Farming Plants Recent Adv. Futur. Prospect. 2012 1 20
151 Schillberg S. Raven N. Fischer R. M Twyman R. Schiermeyer A. Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures Curr. Pharmaceut. Des. 19 2013 5531 5542
152 Chatterjee A. Das N.C. Raha S. Babbit R. Huang Q. Zaitlin D. Maiti I.B. Production of xylanase in transgenic tobacco for industrial use in bioenergy and biofuel applications Vitr. Cell. Dev. Biol. 46 2010 198 209
153 Lai H. Paul A.M. Sun H. He J. Yang M. Bai F. Chen Q. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity Vaccine 36 2018 1846 1852 29490880
154 Clarke J.L. Paruch L. Dobrica M. Caras I. Tucureanu C. Onu A. Ciulean S. Stavaru C. Eerde A. Wang Y. Lettuce‐produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination Plant Biotechnol. J. 15 2017 1611 1621 28419665
155 Santoni M. Ciardiello M.A. Zampieri R. Pezzotti M. Giangrieco I. Rafaiani C. Ciancamerla M. Mari A. Avesani L. Plant-made Bet v 1 for molecular diagnosis Front. Plant Sci. 10 2019 1273 31649716
156 Akers J. Guilfoyle D. Hussong D. McCullough K. Mello R. Singer D. Tidswell E. Tirumalai R. Functional challenges for alternative bacterial endotoxins tests. Part 1. Attributes for alternative tests Am Pharm. Rev 23 2020 76 81
157 Schouest J.M. Luu T.K. Moy R.L. Improved texture and appearance of human facial skin after daily topical application of barley produced, synthetic, human-like epidermal growth factor (EGF) serum J. Drugs Dermatology JDD 11 2012 613 620 22527430
158 Goulet C. Benchabane M. Anguenot R. Brunelle F. Khalf M. Michaud D. A companion protease inhibitor for the protection of cytosol‐targeted recombinant proteins in plants Plant Biotechnol. J. 8 2010 142 154 20051033
159 Zimran A. Gonzalez-Rodriguez D.E. Abrahamov A. Cooper P.A. Varughese S. Giraldo P. Petakov M. Tan E.S. Chertkoff R. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naive or previously treated with imiglucerase, Blood Cells Mol. Dis. 68 2018 163 172
160 Hollak C.E.M. vom Dahl S. Aerts J.M.F.G. Belmatoug N. Bembi B. Cohen Y. Collin-Histed T. Deegan P. van Dussen L. Giraldo P. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease, Blood Cells Mol. Dis. 44 2010 41 47
161 van der Veen S.J. Hollak C.E.M. van Kuilenburg A.B.P. Langeveld M. Developments in the treatment of Fabry disease J. Inherit. Metab. Dis. 43 2020 908 921 32083331
162 Baeshen N.A. Baeshen M.N. Sheikh A. Bora R.S. Ahmed M.M.M. Ramadan H.A.I. Saini K.S. Redwan E.M. Cell factories for insulin production Microb. Cell Fact. 13 2014 1 9 24387764
163 Khan M.S. Joyia F.A. Mustafa G. Seeds as economical production platform for recombinant proteins, Protein Pept Lett 27 2020 89 104
164 Nykiforuk C.L. Boothe J.G. Murray E.W. Keon R.G. Goren H.J. Markley N.A. Moloney M.M. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds Plant Biotechnol. J. 4 2006 77 85 17177787
165 Yoon S. Devaiah S.P. Choi S. Bray J. Love R. Lane J. Drees C. Howard J.H. Hood E.E. Over-expression of the cucumber expansin gene (Cs-EXPA1) in transgenic maize seed for cellulose deconstruction Transgenic Res. 25 2016 173 186 26712321
166 Fox J.L. First plant-made biologic approved Nat. Biotechnol. 30 2012 472 473
167 Kayani W.K. Kiani B.H. Dilshad E. Mirza B. Biotechnological approaches for artemisinin production in Artemisia World J. Microbiol. Biotechnol. 34 2018 1 14
168 Nasiri A. Rashidi-Monfared S. Ebrahimi A. Charkhabi N.F. Moieni A. Metabolic engineering of the diosgenin biosynthesis pathway in Trigonella foenum-graceum hairy root cultures Plant Sci. 323 2022 111410
169 Tu T.Q. Do P.T. Van Nguyen D. Pham N.T.T. Nguyen T.T. Chu M.H. The columbamine O-methyltransferase gene (CoOMT) is capable of increasing alkaloid content in transgenic tobacco plants Mol. Biol. Rep. 49 2022 2667 2675 35059967
170 Fu J. Ren R. Jin S. Fang R. Wen Z. Yang M. Wang X. Liu B. Yin T. Lu G. Overexpression of a putative 12-oxophytodienoate reductase gene, EpOPR1, enhances acetylshikonin production in Echium plantagineum, Vitr Cell Dev. Biol. 58 2022 311 320
171 Xu J. Harnessing the power of plants: a green factory for bioactive compounds Life 13 2023 2041 37895423
172 Schwestka J. Tschofen M. Vogt S. Marcel S. Grillari J. Raith M. Swoboda I. Stoger E. Plant‐derived protein bodies as delivery vehicles for recombinant proteins into mammalian cells Biotechnol. Bioeng. 117 2020 1037 1047 31956981
173 Hood E.E. Kusnadi A. Nikolov Z. Howard J.A. Molecular farming of industrial proteins from transgenic maize BT - chemicals via higher plant bioengineering Shahidi F. Kolodziejczyk P. Whitaker J.R. Munguia A.L. Fuller G. Chem. Via High. Plant Bioeng. 1999 Springer US Boston, MA 127 147 10.1007/978-1-4615-4729-7_11
174 Zimran A. Wajnrajch M. Hernandez B. Pastores G.M. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease, Orphanet J Rare Dis. 13 2018 1 10
175 Eidenberger L. Kogelmann B. Steinkellner H. Plant-based biopharmaceutical engineering Nat. Rev. Bioeng. 1 2023 426 439 37317690
176 Stark M.C. Joubert A.M. Visagie M.H. Molecular farming of pembrolizumab and nivolumab Int. J. Mol. Sci. 24 2023 10045
177 Le Page M. Soya beans get a portion of pork New Sci. 259 2023 17 10.1016/S0262-4079(23)01221-6
178 TurtleTree S. Alternative dairy: state of the industry Ind. Biotechnol. 19 2023 316 325
179 Brown P. Patent Landscape Report-Dairy Milk, Alternative Milks and Milk Hybrids 2024
180 Aktayeva S. Akishev Z.H. Khassenov B. Proteolytic enzymes in cheese making Eurasian J. Appl. Biotechnol. 2018 10.11134/btp.1.2018.2
181 Sahoo A. Mandal A.K. Dwivedi K. Kumar V. A cross talk between the immunization and edible vaccine: current challenges and future prospects Life Sci. 261 2020 118343
182 Kurup V.M. Thomas J. Edible vaccines: promises and challenges Mol. Biotechnol. 62 2020 79 90 31758488
183 Wani K.I. Aftab T. Limitations, biosafety, ethics, regulatory issues in molecular farming in plants Plant Mol. Farming Appl. New Dir. 2022 Springer 61 74
184 Jouzani G.S. Tohidfar M. Plant molecular farming: future prospects and biosafety challenges Biosafety 2 2013 e136
185 Ghignone A.A. The biologic license application New Drug Approv. Process 2016 CRC Press 219 240
186 Grossman M.R. Genetic engineering in the United States: regulation of crops and their food products BT - regulation of genome editing in plant biotechnology Dederer H.-G. Hamburger D. A Comparative Analysis of Regulatory Frameworks of Selected Countries and the EU 2019 Springer International Publishing Cham 263 312 10.1007/978-3-030-17119-3_7
187 Chatzopoulou S. Eriksson N.L. Eriksson D. Improving risk assessment in the European food safety authority: lessons from the European Medicines Agency Front. Plant Sci. 11 2020 349 32318080
188 Ossege C. European Regulatory Agencies in EU Decision-Making: between Expertise and Influence 2016 Springer
189 Shukla M. Al-Busaidi K.T. Trivedi M. Tiwari R.K. Status of research, regulations and challenges for genetically modified crops in India GM Crops Food 9 2018 173 188 30346874
190 Liang J. Yang X. Jiao Y. Wang D. Zhao Q. Sun Y. Li Y. Wu K. The evolution of China's regulation of agricultural biotechnology aBIOTECH 3 2022 237 249 10.1007/s42994-022-00086-1 36533267
191 Ishii T. Regulation of Genome Editing in Plant Biotechnology: Japan, Regul. Genome Ed. Plant Biotechnol. A Comp. Anal. Regul. Fram. Sel. Ctries. EU 2019 239 262
192 Choi I.-Y. Um T. Chung G. Chapter 7 - genetically modified organisms in Korea: state of affairs, policy, and regulation Nawaz M.A. Chung G. Golokhvast K.S. T.-Gmo A.M.B. Tsatsakis P.S. GMOs Polit 2023 Academic Press Stance 115 127 10.1016/B978-0-12-823903-2.00011-1
193 Yang P.-K. Regulatory options for importation of genome-edited foods in taiwan NTU L. Rev. 17 2022 73
194 Amirhusin B. Chapter 8 - genetically modified organism status, regulation, approval, labeling, and consumer perception in ASEAN Nawaz M.A. Chung G. Golokhvast K.S. T.-Gmo A.M.B. Tsatsakis P.S. GMOs Polit 2023 Academic Press Stance 129 150 10.1016/B978-0-12-823903-2.00016-0
195 Sanmugam S. Sivakumar S. Gobalakrishnan T. Sarawanan T. Abeweera P.R. Sandrasaigaran P. Perception and acceptance of genetically modified foods in Malaysia Malaysian J. Sci. Adv. Technol. 2021 144 150
196 Twyman R.M. Host plants, systems and expression strategies for molecular farming, Mol. Farming Plant‐Made Pharm. Tech. Proteins 2004 191 216
197 Koya V. Moayeri M. Leppla S.H. Daniell H. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge Infect. Immun. 73 2005 8266 8274 16299323
198 Zhang X.-X. Yu H. Wang X.-H. Li X.-Z. Zhu Y.-P. Li H.-X. Luo S.-J. Yuan Z.-G. Protective efficacy against Chlamydophila psittaci by oral immunization based on transgenic rice expressing MOMP in mice Vaccine 31 2013 698 703 23196208
199 Nurzijah I. Elbohy O.A. Kanyuka K. Daly J.M. Dunham S. Development of plant-based vaccines for prevention of avian influenza and Newcastle disease in poultry Vaccines 10 2022 478 35335110
200 Gorantala J. Grover S. Goel D. Rahi A. Magani S.K.J. Chandra S. Bhatnagar R. A plant based protective antigen [PA (dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax Vaccine 29 2011 4521 4533 21504775
201 Paolino K.M. Regules J.A. Moon J.E. Ruck R.C. Bennett J.W. Remich S.A. Mills K.T. Lin L. Washington C.N. Fornillos G.A. Lindsey C.Y. O'Brien K.A. Shi M. Mark Jones R. Green B.J. Tottey S. Chichester J.A. Streatfield S.J. Yusibov V. Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: a Phase 1 dose-escalation study in healthy adults Vaccine 40 2022 1864 1871 10.1016/j.vaccine.2022.01.047 35153091
202 Filgueira D.M.P. Zamorano P.I. Domınguez M.G. Taboga O. Zajac M.P.D.M. Puntel M. Romera S.A. Morris T.J. V Borca M. Sadir A.M. Bovine herpes virus gD protein produced in plants using a recombinant tobacco mosaic virus (TMV) vector possesses authentic antigenicity Vaccine 21 2003 4201 4209 14505899
203 Aguirreburualde M.S.P. Gómez M.C. Ostachuk A. Wolman F. Albanesi G. Pecora A. Odeon A. Ardila F. Escribano J.M. Santos M.J.D. Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants Vet. Immunol. Immunopathol. 151 2013 315 324 23291101
204 Ganapathy M. Perumal A. Mohan C. Palaniswamy H. Perumal K. Immunogenicity of Brugia malayi Abundant Larval Transcript-2, a potential filarial vaccine candidate expressed in tobacco Plant Cell Rep. 33 2014 179 188 24277081
205 Arakawa T. Chong D.K.X. Langridge W.H.R. Efficacy of a food plant-based oral cholera toxin B subunit vaccine Nat. Biotechnol. 16 1998 292 297 9528012
206 Jiang X.-L. He Z.-M. Peng Z.-Q. Qi Y. Chen Q. Yu S.-Y. Cholera toxin B protein in transgenic tomato fruit induces systemic immune response in mice Transgenic Res. 16 2007 169 175 17225072
207 Tokuhara D. Yuki Y. Nochi T. Kodama T. Mejima M. Kurokawa S. Takahashi Y. Nanno M. Nakanishi U. Takaiwa F. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine Proc. Natl. Acad. Sci. 107 2010 8794 8799 20421480
208 Karaman S. Cunnick J. Wang K. Expression of the cholera toxin B subunit (CT-B) in maize seeds and a combined mucosal treatment against cholera and traveler's diarrhea Plant Cell Rep. 31 2012 527 537 21938449
209 Kohl T. Hitzeroth I.I. Stewart D. Varsani A. Govan V.A. Christensen N.D. Williamson A.-L. Rybicki E.P. Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study Clin. Vaccine Immunol. 13 2006 845 853 16893983
210 Ghiasi S.M. Salmanian A.-H. Sharafi A. Kazemi R. Jafari M. Chinikar S. Zakeri S. Molecular farming, an effective system for the production of immunogenic Crimean-Congo Hemorrhagic fever virus glycoprotein Prog. Biol. Sci. 2 2012 12 29
211 Hernández M. Cabrera-Ponce J.L. Fragoso G. López-Casillas F. Guevara-García A. Rosas G. León-Ramírez C. Juárez P. Sánchez-García G. Cervantes J. A new highly effective anticysticercosis vaccine expressed in transgenic papaya Vaccine 25 2007 4252 4260 17399859
212 Mason H.S. Haq T.A. Clements J.D. Arntzen C.J. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene Vaccine 16 1998 1336 1343 9682399
213 Tacket C.O. Plant-based vaccines against diarrheal diseases Trans. Am. Clin. Climatol. Assoc. 118 2007 79 18528491
214 Tacket C.O. Plant-based oral vaccines: results of human trials Plant-Produced Microb. Vaccines 2009 103 117
215 Oszvald M. Kang T.-J. Tomoskozi S. Tamas C. Tamas L. Kim T.-G. Yang M.-S. Expression of a synthetic neutralizing epitope of porcine epidemic diarrhea virus fused with synthetic B subunit of Escherichia coli heat labile enterotoxin in rice endosperm Mol. Biotechnol. 35 2007 215 224 17652785
216 Kim T.-G. Kim M.-Y. Kim B.-G. Kang T.-J. Kim Y.-S. Jang Y.-S. Arntzen C.J. Yang M.-S. Synthesis and assembly of Escherichia coli heat-labile enterotoxin B subunit in transgenic lettuce (Lactuca sativa) Protein Expr. Purif. 51 2007 22 27 16919472
217 Moravec T. Schmidt M.A. Herman E.M. Woodford-Thomas T. Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine Vaccine 25 2007 1647 1657 17188785
218 Rigano M.M. Alvarez M.L. Pinkhasov J. Jin Y. Sala F. Arntzen C.J. Walmsley A.M. Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana Plant Cell Rep. 22 2004 502 508 14551732
219 Joensuu J.J. Verdonck F. Ehrström A. Peltola M. Siljander-Rasi H. Nuutila A.-M. Oksman-Caldentey K.-M. Teeri T.H. Cox E. Goddeeris B.M. F4 (K88) fimbrial adhesin FaeG expressed in alfalfa reduces F4+ enterotoxigenic Escherichia coli excretion in weaned piglets Vaccine 24 2006 2387 2394 16378664
220 Rosales-Mendoza S. Soria-Guerra R.E. López-Revilla R. Moreno-Fierros L. Alpuche-Solís Á.G. Ingestion of transgenic carrots expressing the Escherichia coli heat-labile enterotoxin B subunit protects mice against cholera toxin challenge Plant Cell Rep. 27 2008 79 84 17874110
221 Nahampun H.N. Bosworth B. Cunnick J. Mogler M. Wang K. Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice Plant Cell Rep. 34 2015 969 980 25677970
222 Kalthoff D. Giritch A. Geisler K. Bettmann U. Klimyuk V. Hehnen H.-R. Gleba Y. Beer M. Immunization with plant-expressed hemagglutinin protects chickens from lethal highly pathogenic avian influenza virus H5N1 challenge infection J. Virol. 84 2010 12002 12010 20810729
223 D'Aoust M. Lavoie P. Couture M.M. Trépanier S. Guay J. Dargis M. Mongrand S. Landry N. Ward B.J. Vézina L. Influenza virus‐like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice Plant Biotechnol. J. 6 2008 930 940 19076615
224 Kanagarajan S. Tolf C. Lundgren A. Waldenström J. Brodelius P.E. Transient expression of hemagglutinin antigen from low pathogenic avian influenza A (H7N7) in Nicotiana benthamiana PLoS One 7 2012 e33010
225 Mason H.S. Lam D.M. Arntzen C.J. Expression of hepatitis B surface antigen in transgenic plants Proc. Natl. Acad. Sci. 89 1992 11745 11749 1465391
226 Kumar G.B.S. Ganapathi T.R. Revathi C.J. Srinivas L. Bapat V.A. Expression of hepatitis B surface antigen in transgenic banana plants Planta 222 2005 484 493 10.1007/s00425-005-1556-y 15918027
227 Yano A. Maeda F. Takekoshi M. Transgenic tobacco cells producing the human monoclonal antibody to hepatitis B virus surface antigen J. Med. Virol. 73 2004 208 215 15122794
228 Qian B. Shen H. Liang W. Guo X. Zhang C. Wang Y. Li G. Wu A. Cao K. Zhang D. Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds Transgenic Res. 17 2008 621 631 17882531
229 Lou X.-M. Yao Q.-H. Zhang Z. Peng R.-H. Xiong A.-S. Wang H.-K. Expression of the human hepatitis B virus large surface antigen gene in transgenic tomato plants Clin. Vaccine Immunol. 14 2007 464 469 17314228
230 Srinivas L. Sunil Kumar G.B. Ganapathi T.R. Revathi C.J. Bapat V.A. Transient and stable expression of hepatitis B surface antigen in tomato (Lycopersicon esculentum L.) Plant Biotechnol. Rep. 2 2008 1 6
231 Youm J.W. Won Y.S. Jeon J.H. Moon K.B. Kim H.C. Shin K.-S. Joung H. Kim H.S. Antibody responses in mice stimulated by various doses of the potato-derived major surface antigen of hepatitis B virus Clin. Vaccine Immunol. 17 2010 2029 2032 20943879
232 Pniewski T. Kapusta J. Bociąg P. Wojciechowicz J. Kostrzak A. Gdula M. Fedorowicz-Strońska O. Wójcik P. Otta H. Samardakiewicz S. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation J. Appl. Genet. 52 2011 125 136 21107787
233 Hayden C.A. Egelkrout E.M. Moscoso A.M. Enrique C. Keener T.K. Jimenez‐Flores R. Wong J.C. Howard J.A. Production of highly concentrated, heat‐stable hepatitis B surface antigen in maize Plant Biotechnol. J. 10 2012 979 984 22816734
234 Thanavala Y. Mahoney M. Pal S. Scott A. Richter L. Natarajan N. Goodwin P. Arntzen C.J. Mason H.S. Immunogenicity in humans of an edible vaccine for hepatitis B Proc. Natl. Acad. Sci. 102 2005 3378 3382 15728371
235 Huang Z. LePore K. Elkin G. Thanavala Y. Mason H.S. High‐yield rapid production of hepatitis B surface antigen in plant leaf by a viral expression system Plant Biotechnol. J. 6 2008 202 209
236 Zhang H. Liu M. Li Y. Zhao Y. He H. Yang G. Zheng C. Oral immunogenicity and protective efficacy in mice of a carrot-derived vaccine candidate expressing UreB subunit against Helicobacter pylori Protein Expr. Purif. 69 2010 127 131 10.1016/j.pep.2009.07.016 19651219
237 Lindh I. Bråve A. Hallengärd D. Hadad R. Kalbina I. Strid Å. Andersson S. Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses Vaccine 32 2014 2288 2293 24631072
238 Govea-Alonso D.O. Rubio-Infante N. García-Hernández A.L. Varona-Santos J.T. Korban S.S. Moreno-Fierros L. Rosales-Mendoza S. Immunogenic properties of a lettuce-derived C4 (V3) 6 multiepitopic HIV protein Planta 238 2013 785 792 23897297
239 Rubio-Infante N. Govea-Alonso D.O. Alpuche-Solís Á.G. García-Hernández A.L. Soria-Guerra R.E. Paz-Maldonado L.M. Ilhuicatzi-Alvarado D. Varona-Santos J.T. Verdín-Terán L. Korban S.S. A chloroplast-derived C4V3 polypeptide from the human immunodeficiency virus (HIV) is orally immunogenic in mice Plant Mol. Biol. 78 2012 337 349 22228408
240 Scotti N. Alagna F. Ferraiolo E. Formisano G. Sannino L. Buonaguro L. De Stradis A. Vitale A. Monti L. Grillo S. High-level expression of the HIV-1 Pr55 gag polyprotein in transgenic tobacco chloroplasts Planta 229 2009 1109 1122 19234717
241 Cervera L. Gòdia F. Tarrés-Freixas F. Aguilar-Gurrieri C. Carrillo J. Blanco J. Gutiérrez-Granados S. Production of HIV-1-based virus-like particles for vaccination: achievements and limits Appl. Microbiol. Biotechnol. 103 2019 7367 7384 31372703
242 Gonzalez‐Rabade N. McGowan E.G. Zhou F. McCabe M.S. Bock R. Dix P.J. Gray J.C. Ma J.K. Immunogenicity of chloroplast‐derived HIV‐1 p24 and a p24‐Nef fusion protein following subcutaneous and oral administration in mice Plant Biotechnol. J. 9 2011 629 638 21443546
243 Monroy-García A. Gómez-Lim M.A. Weiss-Steider B. Hernández-Montes J. Huerta-Yepez S. Rangel-Santiago J.F. Santiago-Osorio E. Mora García M. de L. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model Arch. Virol. 159 2014 291 305 23990055
244 Varsani A. Williamson A.-L. Rose R.C. Jaffer M. Rybicki E.P. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi Arch. Virol. 148 2003 1771 1786 14505089
245 Hongli L. Xukui L. Ting L. Wensheng L. Lusheng S. Jin Z. Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice Hum. Vaccines Immunother. 9 2013 83 89
246 Zhou J.-Y. Cheng L.-Q. Zheng X.-J. Wu J.-X. Shang S.-B. Wang J.-Y. Chen J.-G. Generation of the transgenic potato expressing full-length spike protein of infectious bronchitis virus J. Biotechnol. 111 2004 121 130 15219399
247 Wu J. Yu L. Li L. Hu J. Zhou J. Zhou X. Oral immunization with transgenic rice seeds expressing VP2 protein of infectious bursal disease virus induces protective immune responses in chickens Plant Biotechnol. J. 5 2007 570 578 17561926
248 Shoji Y. Farrance C.E. Bautista J. Bi H. Musiychuk K. Horsey A. Park H. Jaje J. Green B.J. Shamloul M. A plant‐based system for rapid production of influenza vaccine antigens, Influenza Other Respi Viruses 6 2012 204 210
249 Pillet S. Couillard J. Trépanier S. Poulin J.-F. Yassine-Diab B. Guy B. Ward B.J. Landry N. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—two randomized Phase II clinical trials in 18 to 49 and≥ 50 years old adults PLoS One 14 2019 e0216533
250 Wang Y. Deng H. Zhang X. Xiao H. Jiang Y. Song Y. Fang L. Xiao S. Zhen Y. Chen H. Generation and immunogenicity of Japanese encephalitis virus envelope protein expressed in transgenic rice Biochem. Biophys. Res. Commun. 380 2009 292 297 10.1016/j.bbrc.2009.01.061 19166811
251 Uvarova E.A. Belavin P.A. V Permyakova N. Zagorskaya A.A. V Nosareva O. Kakimzhanova A.A. V Deineko E. Oral immunogenicity of plant-made Mycobacterium tuberculosis ESAT6 and CFP10 BioMed Res. Int. 2013 2013
252 Lakshmi P.S. Verma D. Yang X. Lloyd B. Daniell H. Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro PLoS One 8 2013 e54708
253 Gómez E. Zoth S.C. Asurmendi S. Rovere C.V. Berinstein A. Expression of hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus in agroinfiltrated Nicotiana benthamiana plants J. Biotechnol. 144 2009 337 340 19799942
254 Guerrero-Andrade O. Loza-Rubio E. Olivera-Flores T. Fehérvári-Bone T. Gómez-Lim M.A. Expression of the Newcastle disease virus fusion protein in transgenic maize and immunological studies Transgenic Res. 15 2006 455 463 16906446
255 Hahn B.-S. Jeon I.-S. Jung Y.-J. Kim J.-B. Park J.-S. Ha S.-H. Kim K.-H. Kim H.-M. Yang J.-S. Kim Y.-H. Expression of hemagglutinin-neuraminidase protein of Newcastle disease virus in transgenic tobacco Plant Biotechnol. Rep. 1 2007 85 92
256 Santi L. Batchelor L. Huang Z. Hjelm B. Kilbourne J. Arntzen C.J. Chen Q. Mason H.S. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles Vaccine 26 2008 1846 1854 10.1016/j.vaccine.2008.01.053 18325641
257 Davoodi‐Semiromi A. Schreiber M. Nalapalli S. Verma D. Singh N.D. Banks R.K. Chakrabarti D. Daniell H. Chloroplast‐derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery Plant Biotechnol. J. 8 2010 223 242 20051036
258 Chan H. Xiao Y. Weldon W.C. Oberste S.M. Chumakov K. Daniell H. Cold chain and virus‐free chloroplast‐made booster vaccine to confer immunity against different poliovirus serotypes Plant Biotechnol. J. 14 2016 2190 2200 27155248
259 Castanon S. Marin M.S. Martin-Alonso J.M. Boga J.A. Casais R. Humara J.M. Ordas R.J. Parra F. Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus J. Virol. 73 1999 4452 4455 10196345
260 Perea Arango I. Loza Rubio E. Rojas Anaya E. Olivera Flores T. Gonzalez de la Vara L. Gómez Lim M.A. Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice Plant Cell Rep. 27 2008 677 685 18270708
261 Khandelwal A. Sita G.L. Shaila M.S. Oral immunization of cattle with hemagglutinin protein of rinderpest virus expressed in transgenic peanut induces specific immune responses Vaccine 21 2003 3282 3289 12804859
262 Dong J.-L. Liang B.-G. Jin Y.-S. Zhang W.-J. Wang T. Oral immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus infection Virology 339 2005 153 163 15992851
263 Pogrebnyak N. Golovkin M. Andrianov V. Spitsin S. Smirnov Y. Egolf R. Koprowski H. Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine Proc. Natl. Acad. Sci. 102 2005 9062 9067 15956182
264 Zheng N. Xia R. Yang C. Yin B. Li Y. Duan C. Liang L. Guo H. Xie Q. Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice Vaccine 27 2009 5001 5007 19523911
265 Ortega-Rivera O.A. Shin M.D. Chen A. Beiss V. Moreno-Gonzalez M.A. Lopez-Ramirez M.A. Reynoso M. Wang H. Hurst B.L. Wang J. Trivalent subunit vaccine candidates for COVID-19 and their delivery devices J. Am. Chem. Soc. 143 2021 14748 14765 34490778
266 Ward B.J. Gobeil P. Séguin A. Atkins J. Boulay I. Charbonneau P.-Y. Couture M. D'Aoust M.-A. Dhaliwall J. Finkle C. Hager K. Mahmood A. Makarkov A. Cheng M.P. Pillet S. Schimke P. St-Martin S. Trépanier S. Landry N. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19 Nat. Med. 27 2021 1071 1078 10.1038/s41591-021-01370-1 34007070
267 Hager K.J. Pérez Marc G. Gobeil P. Diaz R.S. Heizer G. Llapur C. Makarkov A.I. Vasconcellos E. Pillet S. Riera F. Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine N. Engl. J. Med. 386 2022 2084 2096 35507508
268 Royal J.M. Simpson C.A. McCormick A.A. Phillips A. Hume S. Morton J. Shepherd J. Oh Y. Swope K. DeBeauchamp J.L. Development of a SARS-CoV-2 vaccine candidate using plant-based manufacturing and a tobacco mosaic virus-like nano-particle Vaccines 9 2021 1347 34835278
269 Albarracín R.M. Becher M.L. Farran I. Sander V.A. Corigliano M.G. Yácono M.L. Pariani S. López E.S. Veramendi J. Clemente M. The fusion of Toxoplasma gondii SAG1 vaccine candidate to Leishmania infantum heat shock protein 83‐kDa improves expression levels in tobacco chloroplasts Biotechnol. J. 10 2015 748 759 25823559
270 Tuboly T. Yu W. Bailey A. Degrandis S. Du S. Erickson L. Nagy E. Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants Vaccine 18 2000 2023 2028 10706964
271 Lamphear B.J. Jilka J.M. Kesl L. Welter M. Howard J.A. Streatfield S.J. A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine Vaccine 22 2004 2420 2424 15193404
272 Limaye A. Koya V. Samsam M. Daniell H. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 20 2006 959
273 Daniell H. Lee S.-B. Panchal T. Wiebe P.O. Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts11Edited Chua N.-H. J. Mol. Biol. 311 2001 1001 1009 10.1006/jmbi.2001.4921 11531335
274 Alvarez M.L. Pinyerd H.L. Crisantes J.D. Rigano M.M. Pinkhasov J. Walmsley A.M. Mason H.S. Cardineau G.A. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice Vaccine 24 2006 2477 2490 16442673
275 Arlen P.A. Singleton M. Adamovicz J.J. Ding Y. Davoodi-Semiromi A. Daniell H. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts Infect. Immun. 76 2008 3640 3650 18505806
276 Larrick J.W. Yu L. Chen J. Jaiswal S. Wycoff K. Production of antibodies in transgenic plants Res. Immunol. 149 1998 603 608 9835425
277 Zeitlin L. Olmsted S.S. Moench T.R. Co M.S. Martinell B.J. Paradkar V.M. Russell D.R. Queen C. Cone R.A. Whaley K.J. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes Nat. Biotechnol. 16 1998 1361 1364 9853620
278 Cone R.A. Whaley K.J. Topical Application of Antibodies for Contraception and for Prophylaxis against Sexually Transmitted Diseases 2002
279 Raven N. Rasche S. Kuehn C. Anderlei T. Klöckner W. Schuster F. Henquet M. Bosch D. Büchs J. Fischer R. Scaled‐up manufacturing of recombinant antibodies produced by plant cells in a 200‐L orbitally‐shaken disposable bioreactor Biotechnol. Bioeng. 112 2015 308 321 25117428
280 Rademacher T. Sack M. Arcalis E. Stadlmann J. Balzer S. Altmann F. Quendler H. Stiegler G. Kunert R. Fischer R. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV‐1 and contains predominantly single‐GlcNAc N‐glycans Plant Biotechnol. J. 6 2008 189 201 17979949
281 Ramessar K. Rademacher T. Sack M. Stadlmann J. Platis D. Stiegler G. Labrou N. Altmann F. Ma J. Stöger E. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission Proc. Natl. Acad. Sci. 105 2008 3727 3732 18316741
282 Krystel J. Liu H. Hartung J. Stover E. Novel plantibodies show promise to protect citrus from greening disease J. Am. Soc. Hortic. Sci. 146 2021 377 386 10.21273/JASHS05078-21
283 Ma J.K.-C. Hikmat B.Y. Wycoff K. Vine N.D. Chargelegue D. Yu L. Hein M.B. Lehner T. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans Nat. Med. 4 1998 601 606 9585235
284 Stöger E. Vaquero C. Torres E. Sack M. Nicholson L. Drossard J. Williams S. Keen D. Perrin Y. Christou P. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies Plant Mol. Biol. 42 2000 583 590 10809004
285 Torres E. Vaquero C. Nicholson L. Sack M. Stöger E. Drossard J. Christou P. Fischer R. Perrin Y. Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies Transgenic Res. 8 1999 441 449 10767987
286 Vaquero C. Sack M. Chandler J. Drossard J. Schuster F. Monecke M. Schillberg S. Fischer R. Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves Proc. Natl. Acad. Sci. 96 1999 11128 11133 10500141
287 Hernández-Velázquez A. López-Quesada A. Ceballo-Cámara Y. Cabrera-Herrera G. Tiel-González K. Mirabal-Ortega L. Pérez-Martínez M. Pérez-Castillo R. Rosabal-Ayán Y. Ramos-González O. Tobacco seeds as efficient production platform for a biologically active anti-HBsAg monoclonal antibody Transgenic Res. 24 2015 897 909 26109093
288 Brodzik R. Glogowska M. Bandurska K. Okulicz M. Deka D. Ko K. van der Linden J. Leusen J.H.W. Pogrebnyak N. Golovkin M. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells Proc. Natl. Acad. Sci. 103 2006 8804 8809 16720700
289 Villani M.E. Morgun B. Brunetti P. Marusic C. Lombardi R. Pisoni I. Bacci C. Desiderio A. Benvenuto E. Donini M. Plant pharming of a full‐sized, tumour‐targeting antibody using different expression strategies Plant Biotechnol. J. 7 2009 59 72 18793269
290 De Muynck B. Navarre C. Nizet Y. Stadlmann J. Boutry M. Different subcellular localization and glycosylation for a functional antibody expressed in Nicotiana tabacum plants and suspension cells Transgenic Res. 18 2009 467 482 10.1007/s11248-008-9240-1 19140023
291 Hull A.K. Criscuolo C.J. Mett V. Groen H. Steeman W. Westra H. Chapman G. Legutki B. Baillie L. Yusibov V. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax Vaccine 23 2005 2082 2086 15755575
292 Girard L.S. Fabis M.J. Bastin M. Courtois D. Pétiard V. Koprowski H. Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture Biochem. Biophys. Res. Commun. 345 2006 602 607 16690026
293 Kamenarova K. Abumhadi N. Gecheff K. Atanassov A. Molecular farming in plants: an approach of agricultural biotechnology J. Cell Mol. Biol. 4 2005 77 86
294 van Dolleweerd C.J. Teh A.Y.H. Banyard A.C. Both L. Lotter-Stark H.C.T. Tsekoa T. Phahladira B. Shumba W. Chakauya E. Sabeta C.T. Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody J. Infect. Dis. 210 2014 200 208 24511101
295 Almquist K.C. McLean M.D. Niu Y. Byrne G. Olea-Popelka F.C. Murrant C. Barclay J. Hall J.C. Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco Vaccine 24 2006 2079 2086 10.1016/j.vaccine.2005.11.014 16337316
296 Makvandi-Nejad S. McLean M.D. Hirama T. Almquist K.C. MacKenzie C.R. Hall J.C. Transgenic tobacco plants expressing a dimeric single-chain variable fragment (scFv) antibody against Salmonella enterica serotype paratyphi B Transgenic Res. 14 2005 785 792 10.1007/s11248-005-7461-0 16245169
297 Stoger E. Sack M. Fischer R. Christou P. Plantibodies: applications, advantages and bottlenecks Curr. Opin. Biotechnol. 13 2002 161 166 11950570
298 Juarez P. Huet-Trujillo E. Sarrion-Perdigones A. Falconi E.E. Granell A. Orzaez D. Combinatorial analysis of secretory immunoglobulin A (sIgA) expression in plants Int. J. Mol. Sci. 14 2013 6205 6222 23507755
299 Hood E.E. Woodard S.L. Horn M.E. Monoclonal antibody manufacturing in transgenic plants—myths and realities Curr. Opin. Biotechnol. 13 2002 630 635 12482526
300 Stoger E. Sack M. Nicholson L. Fischer R. Christou P. Recent progress in plantibody technology Curr. Pharmaceut. Des. 11 2005 2439 2457
301 Virdi V. Coddens A. De Buck S. Millet S. Goddeeris B.M. Cox E. De Greve H. Depicker A. Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection Proc. Natl. Acad. Sci. 110 2013 11809 11814 23801763
302 De Meyer T. Laukens B. Nolf J. Van Lerberge E. De Rycke R. De Beuckelaer A. De Buck S. Callewaert N. Depicker A. Comparison of VHH‐Fc antibody production in Arabidopsis thaliana, Nicotiana benthamiana and Pichia pastoris Plant Biotechnol. J. 13 2015 938 947 25641071
303 Mulangu S. Dodd L.E. Davey R.T. Jr. Tshiani Mbaya O. Proschan M. Mukadi D. Lusakibanza Manzo M. Nzolo D. Tshomba Oloma A. Ibanda A. A randomized, controlled trial of Ebola virus disease therapeutics N. Engl. J. Med. 381 2019 2293 2303 31774950
304 Pogue G.P. Vojdani F. Palmer K.E. Hiatt E. Hume S. Phelps J. Long L. Bohorova N. Kim D. Pauly M. Production of pharmaceutical‐grade recombinant aprotinin and a monoclonal antibody product using plant‐based transient expression systems Plant Biotechnol. J. 8 2010 638 654 20514694
305 Wang Y.-P. Wei Z.-Y. Zhong X.-F. Lin C.-J. Cai Y.-H. Ma J. Zhang Y.-Y. Liu Y.-Z. Xing S.-C. Stable expression of basic fibroblast growth factor in chloroplasts of tobacco Int. J. Mol. Sci. 17 2015 19 26703590
306 Ahmad A.R. Kaewpungsup P. Khorattanakulchai N. Rattanapisit K. Pavasant P. Phoolcharoen W. Recombinant human dentin matrix protein 1 (hDMP1) expressed in Nicotiana benthamiana potentially induces osteogenic differentiation Plants 8 2019 566 31816999
307 Büttner‐Mainik A. Parsons J. Jérôme H. Hartmann A. Lamer S. Schaaf A. Schlosser A. Zipfel P.F. Reski R. Decker E.L. Production of biologically active recombinant human factor H in Physcomitrella Plant Biotechnol. J. 9 2011 373 383 20723134
308 Shaaltiel Y. Bartfeld D. Hashmueli S. Baum G. Brill‐Almon E. Galili G. Dym O. Boldin‐Adamsky S.A. Silman I. Sussman J.L. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system Plant Biotechnol. J. 5 2007 579 590 17524049
309 Shaaltiel Y. Gingis–Velitski S. Tzaban S. Fiks N. Tekoah Y. Aviezer D. Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease Plant Biotechnol. J. 13 2015 1033 1040 25828481
310 Green B.J. Fujiki M. Mett V. Kaczmarczyk J. Shamloul M. Musiychuk K. Underkoffler S. Yusibov V. Mett V. Transient protein expression in three Pisum sativum (green pea) varieties Biotechnol. J. 4 2009 230 237 19156736
311 Xu J. Okada S. Tan L. Goodrum K.J. Kopchick J.J. Kieliszewski M.J. Human growth hormone expressed in tobacco cells as an arabinogalactan-protein fusion glycoprotein has a prolonged serum life Transgenic Res. 19 2010 849 867 20135224
312 Negrouk V. Eisner G. Lee H. Han K. Taylor D. Wong H.C. Highly efficient transient expression of functional recombinant antibodies in lettuce Plant Sci. 169 2005 433 438
313 Giddings G. Allison G. Brooks D. Carter A. Transgenic plants as factories for biopharmaceuticals Nat. Biotechnol. 18 2000 1151 1155 11062432
314 Kusnadi A.R. Nikolov Z.L. Howard J.A. Production of recombinant proteins in transgenic plants: practical considerations Biotechnol. Bioeng. 56 1997 473 484 18642268
315 Cramer C.L. Boothe J.G. Oishi K.K. Transgenic plants for therapeutic proteins: linking upstream and downstream strategies Plant Biotechnol. 2000 95 118
316 Ruggiero F. Exposito J.-Y. Bournat P. Gruber V. Perret S. Comte J. Olagnier B. Garrone R. Theisen M. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants FEBS Lett. 469 2000 132 136 10708770
317 Yang D. Guo F. Liu B. Huang N. Watkins S.C. Expression and localization of human lysozyme in the endosperm of transgenic rice Planta 216 2003 597 603 12569401
318 Fernández‐San Millán A. Mingo‐Castel A. Miller M. Daniell H. A chloroplast transgenic approach to hyper‐express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation Plant Biotechnol. J. 1 2003 71 79 17147744
319 Staub J.M. Garcia B. Graves J. Hajdukiewicz P.T.J. Hunter P. Nehra N. Paradkar V. Schlittler M. Carroll J.A. Spatola L. High-yield production of a human therapeutic protein in tobacco chloroplasts Nat. Biotechnol. 18 2000 333 338 10700152
320 Markley N. Nykiforuk C. Boothe J. Moloney M. Producing proteins using transgenic oilbody-oleosin technology Biopharm Int. 19 2006
321 Li D. O'Leary J. Huang Y. Huner N.P.A. Jevnikar A.M. Ma S. Expression of cholera toxin B subunit and the B chain of human insulin as a fusion protein in transgenic tobacco plants Plant Cell Rep. 25 2006 417 424 16322994
322 Liu C. Towler M.J. Medrano G. Cramer C.L. Weathers P.J. Production of mouse interleukin‐12 is greater in tobacco hairy roots grown in a mist reactor than in an airlift reactor Biotechnol. Bioeng. 102 2009 1074 1086 18988263
323 Nandi S. Yalda D. Lu S. Nikolov Z. Misaki R. Fujiyama K. Huang N. Process development and economic evaluation of recombinant human lactoferrin expressed in rice grain Transgenic Res. 14 2005 237 249 16145832
324 Guan C. Du X. Wang G. Ji J. Jin C. Li X. Expression of biologically active anti-thrombosis protein lumbrokinase in edible sunflower seed kernel J. Plant Biochem. Biotechnol. 23 2014 257 265
325 Yang D. Wu L. Hwang Y.-S. Chen L. Huang N. Expression of the REB transcriptional activator in rice grains improves the yield of recombinant proteins whose genes are controlled by a Reb-responsive promoter Proc. Natl. Acad. Sci. 98 2001 11438 11443 11572990
326 Bohmert-Tatarev K. McAvoy S. Daughtry S. Peoples O.P. Snell K.D. High levels of bioplastic are produced in fertile transplastomic tobacco plants engineered with a synthetic operon for the production of polyhydroxybutyrate Plant Physiol. 155 2011 1690 1708 21325565
327 Castiglia D. Sannino L. Marcolongo L. Ionata E. Tamburino R. De Stradis A. Cobucci-Ponzano B. Moracci M. La Cara F. Scotti N. High-level expression of thermostable cellulolytic enzymes in tobacco transplastomic plants and their use in hydrolysis of an industrially pretreated Arundo donax L. biomass Biotechnol. Biofuels 9 2016 1 16 26734071
328 Stoger E. Fischer R. Moloney M. Ma J.K.-C. Plant molecular pharming for the treatment of chronic and infectious diseases Annu. Rev. Plant Biol. 65 2014 743 768 24579993
329 Xu X. Gan Q. Clough R.C. Pappu K.M. Howard J.A. Baez J.A. Wang K. Hydroxylation of recombinant human collagen type I alpha 1 in transgenic maize co-expressed with a recombinant human prolyl 4-hydroxylase BMC Biotechnol. 11 2011 1 12 21208406
330 Habibi P. De Sa M.F.G. Makhzoum A. Malik S. da Silva A.L.L. Hefferon K. Soccol C.R. Bioengineering hairy roots: phytoremediation, secondary metabolism, molecular pharming, plant-plant interactions and biofuels Sustain. Agric. Rev. 2017 213 251
